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MOLECULAR MODELING OF SIGMA 1 AND SIGMA 2 RECEPTOR
LIGANDS: PHARMACOPHORE DEVELOPMENT AND COMPARISON
USING DISCOTECH AND BIOACTIVITY PREDICTION COMPARISON OF AB
INITIO AND DENSITY FUNCTIONAL COMFA STUDIES FOR SPIRO AND
OTHER RECEPTOR LIGANDS
ABSTRACT
by
Lisa M. Kardos
The role of the biological receptor is currently being studied by researchers in medicine.
Information about sigma receptors in particular can be gained by studying the ligands
associated with each type, sigma 1 or sigma 2. Sigma 1 receptor ligands consist of drug
candidates that often have psychiatric and neurological applications; sigma 2 receptor
ligands consist of drug candidates that have been linked with cancer treatment among
other applications.
Molecular modeling of biological receptor ligands often encompasses
pharmacophore development and Comparative Molecular Field Analysis (CoMFA).
Pharmacophore models are developed to understand the unique features such as binding
groups that make a ligand bioactive. CoMFA uses experimental data of molecules,
considered to be a training set, to yield bioactivity prediction for those molecules; this is
the internal validation piece. An external test set of molecules with known experimental
data can then be used for validation of the CoMFA models. The resulting CoMFA
models create contour maps which provide information about the sterics and
electrostatics, resulting in the ability to apply this information during the design of new
ligands. The new molecules can then be tested in the validated CoMFA models to yield
bioactivity predictions.

This study describes the development of pharmacophore and Comparative
Molecular Field Analysis (CoMFA) models for sigma 1 and sigma 2 receptor ligands.
Distance Comparisons (DISCOtech) in SYBYL-X 2.1 is used as a tool for the
pharmacophore development. A pharmacophore is developed for each individual class of
molecules and for the entire set of sigma 1 molecules and sigma 2 molecules analyzed
during this study, respectively. All compounds are calculated in SPARTAN ’14 using ab
initio and density functional calculation methods HF/6-31G* and B3LYP/6-31G* prior to
model development. These calculations determine the geometry optimization and
electrostatic charges for each molecule.
CoMFA studies, utilizing SYBYL-X 2.1, are performed for 41 sigma 1 receptor
ligands using the radioligand [H3](+) pentazocine and for 31 sigma 2 receptor ligands
using [H3](+) DTG in the presence of pentazocine. The CoMFA models developed
confirm that bioactivity prediction comparison is reliable for both HF/6-31G* and
B3LYP/6-31G* optimized geometries for both sigma 1 and sigma 2 ligands; this is
verified via both internal and external validation methods. The CoMFA contour maps are
utilized to design new sigma 1 and sigma 2 ligands; the newly designed ligands are
predicted to be highly active according to the CoMFA models. This study also compares
CoMFA models between the ab initio and density functional calculation levels for sigma
1 and sigma 2 ligands, respectively. The similarities and differences between sigma 1 and
sigma 2 receptor ligands are also analyzed via the developed pharmacophore models and
generated CoMFA contour maps.
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CHAPTER 1
INTRODUCTION

1.1 Overview
Chemical engineering and chemistry as disciplines interestingly converge at certain
points. In this particular study, this convergence occurs conceptually with molecular
modeling related drug design as it pertains to chemical reaction kinetics and
thermodynamics. These are the same fundamentals which drive the interaction of
biological receptors and their ligands; the binding of ligands to receptors results in a
cascade of biological and medicinal activity, hence the usefulness in designing drugs
targeted to receptors (Sharma, 2012).
Sigma receptors have become key therapeutic targets in biological and medicinal
chemistry studies. Sigma receptors are considered to be a unique receptor family that is
localized in the cell cytoplasm of the brain; internal organs; and endocrine, immune and
reproductive tissues and they are overexpressed by several tumor cell lines (Berardi et al.,
2004). There are two sub-types that are currently identified in the literature, sigma 1 and
sigma 2. Receptor ligands, particularly highly active ones, are critical since binding leads
to biological effects (Patrick, 2005). The sigma 1 subtype is involved in socially
important human diseases such as schizophrenia, depression, Alzheimer’s disease and
drug/alcohol dependence (Brune and Wünsch, 2013). The sigma 1 receptor is also being
studied for the treatment of several pain conditions, either alone or in combination with
known analgesics (Zamanillo et al., 2013). The sigma 2 subtype is currently being studied
as a target for tumor apoptosis and as biomarkers in cancer imaging (Abate et al., 2014;
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Berardi et al., 2004).
Computers have become an essential tool in modern medicinal chemistry and are
important in both drug discovery and drug development (Patrick, 2005). Molecular
modeling, including methods such as quantum mechanics, pharmacophore derivation and
CoMFA (Comparative Molecular Field Analysis), yielded results for the following
objectives:
1) Derive pharmacophore models for each selected series of active sigma 1
ligand classes
2) Derive a representative (comprehensive) pharmacophore for the selected
sigma 1 ligand series
3) Perform an alignment of 41 compounds to construct a validated CoMFA for
sigma 1 receptor ligands.
4) Compare density functional and ab initio calculations to the CoMFA studies
on sigma 1 ligands.
5) Predict the bioactivities (binding affinities) of the selected sigma 1 receptor
ligands.
6) Design new sigma 1 ligands (potential drug candidates) from CoMFA results.
7) Derive pharmacophore models for each selected series of active sigma 2
classes.
8) Derive a representative (comprehensive) pharmacophore for the selected
sigma 2 series.
9) Perform an alignment of 31 compounds to construct a validated CoMFA for
sigma 2 receptor ligands.
10) Compare density functional and ab initio calculations to the CoMFA studies
on sigma 2 ligands.
11) Predict the bioactivities (binding affinities) of the selected sigma 2 receptor
ligands.
12) Design new sigma 2 ligands (potential drug candidates) from CoMFA results.
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13) Analyze the resulting pharmacophores and models determined by the
aforementioned approaches to yield a comparison of the sigma 1 and sigma 2
receptor ligands.
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CHAPTER 2
BACKGROUND

2.1 Biological Activity and Interactions of Receptor Ligands
The term receptor has been formally defined as a cellular macromolecule that is
concerned directly and specifically with chemical signaling between and within cells; the
combination of an appropriate ligand with its receptor(s) initiates a change in cell
function (Cannon, 2007). Essentially a ligand is a drug and the affinity is a measure of
how strongly a drug binds to a receptor (Patrick, 2005). The corresponding equation
describing the drug-receptor relationship, Equation 2.1, along with the equation for Kd,
Equation 2.2. the dissociation binding constant, are as follows (Silverman, 2004):

𝑑𝑟𝑢𝑔 + 𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 ↔ 𝑑𝑟𝑢𝑔 − 𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 𝑐𝑜𝑚𝑝𝑙𝑒𝑥

𝐾𝑑 =

[𝑑𝑟𝑢𝑔][𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟]
[𝑑𝑟𝑢𝑔 − 𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 𝑐𝑜𝑚𝑝𝑙𝑒𝑥]

(2.1)

(2.2)

The dissociation constant is a measure of the strength of the interaction between the drug
candidate and the receptor (target); Kd is often referred to as the inhibition constant, Ki,
for an enzyme inhibitor (Berg and Stryer, 2005). It is important to note that the literature
for sigma receptor ligands typically uses Ki to discuss the affinity values. After
synthesizing drug targets, researchers use radioligand labelling where a ligand for the
target receptor is labelled with radioactivity and is added to cells or tissue such that it can
bind to the receptors present; once an equilibrium has been reached, the unbound ligands
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are removed thereby allowing measurement of radioactivity which relates to the extent of
binding (Patrick, 2005). After data is collected from experiments and plotted, a
displacement or inhibition curve can be generated to yield an IC50 value (Patrick, 2005).
Some researchers use computer software to aid in this area in the literature. Note that IC50
(or I50) expresses the concentration of inhibitor required to produce 50 percent inhibition
of an enzymatic reaction (Cheng and Prusoff, 1973). Ki is the same as the IC50 value if
non-competitive interactions are involved; for compounds that are in competition with
the radioligand for the binding site, the Ki depends on the following equation (Cheng and
Prusoff, 1973; Patrick, 2005):

𝐾𝑖 =

𝐼𝐶50
1 + [𝐿]𝑡𝑜𝑡 /𝐾𝑑

(2.3)

Note that competitive inhibition is the focus of this study. Competitive inhibition means
that the inhibitor binds to the same site on the enzyme as the substrate, forming an
abortive complex; the substrate and inhibitor compete for the same site so that only one
enzyme-inhibitor complex is possible (Cornish-Bowden, 1976). pKi is also a tool that has
been used by the Gund group in previous work, particularly in CoMFA. pKi is defined in
Equation 2.4 as:

pKi = -log[Ki]

(2.4)

The pKi values were calculated by the Ki values provided in the literature which were
collected either in vitro or in vivo for the various compounds studied.
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The aforementioned information regarding the basic enzyme-type kinetics of
receptor ligands explains a piece of the drug-receptor complex. It is important to note that
the interactions involved in the drug-receptor complex are the same forces experienced
by all interacting organic molecules and include covalent bonding, ionic (electrostatic)
interactions, ion-dipole and dipole-dipole interactions, hydrogen bonding, charge-transfer
interactions, hydrophobic interactions, and van der Waals interactions (Silverman, 2004).
Electrostatic properties of the receptor ligands will be discussed and studied when the
CoMFA studies are complete, whereas some of the structure-activity relationships with
the hydrophobic groups within the receptor ligands, a key property of the pharmacophore
models in this study, will be discussed in Chapters 3 and 4.

2.2 Pharmacophore Identification and QSAR Methodology
Pharmacophore identification for the ligands in this study is a key aspect of the research.
Pharmacophores allow us to understand drug-receptor interactions on the molecular level
especially if there is not much information about the structure of the receptors themselves
(Höltje, 1996).

A pharmacophore represents the relative position of important binding

groups in space and disregards the molecular structure that holds them there (Patrick,
2005). A majority of drugs exert their action via specific binding to biomacromolecules,
hence the importance of the binding groups (Höltje, 1996). Typical binding sites include
hydrophobic groups, aromatic rings, positive nitrogen atoms, acceptor sites (lone pair of
electrons), donor sites and others.
When a pharmacophore has been identified, structures can be analyzed to
determine if they can adopt a stable conformation which will contain the pharmacophore;
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this approach, while ensuring that there are no steric clashes with the binding site, will
help identify the active structures (Patrick, 2005). It is important to note that this process
can be conducted manually or via a software program. This study uses the SYBYL suite
which includes DISCOtech (DIStance COmparison) which will be discussed further in
Chapters 3 and 4. Eventually the pharmacophore model can be useful to help identify
other potential ligands if the ligands have a close fit to the model with the appropriate
binding groups.
When beginning the pharmacophore identification process, one should determine
the appropriate calculation levels to be used to minimize the energy (at the equilibrium
geometry) for each molecule. More sophisticated methods include density functional and
ab initio optimizations; both are used in this study.
QSAR (Quantitative Structure-Activity Relationship) models, particularly 3D
methods, consider properties of a molecule as opposed to individual substituents or
moieties, typically utilizing software and hardware to achieve this; the premise is based
on the assumption that the most important features about a molecule are its size, shape
and electrostatic properties (Patrick, 2005). There are several approaches to QSAR but
the common one is CoMFA which is used in this study based on the assumption that the
ligand-receptor interactions are non-covalent and that biological activity correlate with
the changes in the steric and/or electrostatic fields of the drug molecules (Patrick, 2005).
The first steps in CoMFA include the aforementioned determination of the active
conformations and consequently pharmacophore identification. The next step is to place
the pharmacophore into a lattice where it will act as a reference when positioning other
molecules into the lattice; each molecule will be matched up to the pharmacophore

7

(Patrick, 2005). The steric and electrostatic fields around each molecule are measured.
The measurements are conducted by putting a probe atom (i.e. carbocation) and
determining the attraction or repulsion between the probe and the molecule at each of the
lattice points, consequently calculating steric, electrostatic and hydrophobic interaction
energies shown through countour lines (Patrick, 2005). The CoMFA is not complete until
statistical procedures are followed to validate the measurements to determine the
prediction accuracy for biological activity (Martin and Lin, 1996; Patrick, 2005).

2.2.1

Partial Least Squares

Validation techniques are an important aspect of research. Particularly in this study, as
with most research studies utilizing CoMFA or QSAR techniques, PLS (partial least
squares) needs to be incorporated through cross-validation. The concept of crossvalidation essentially means that one or more active ligands are left out during the
process of the computer deriving an equation or relationship, in this case for biological
activity; this is often referred to as the “leave-one-out” process (Martin and Lin, 1996).
The resulting equation is then applied to predict the activity for the omitted ligand(s).
When this process is complete, a final formula is obtained. The predictability of the final
formula is represented by the cross-validated correlation coefficient, PRESS (Predictive
Residual Sum of Squares), r2, which is often referred to as q2 (Leach, 1996; Patrick,
2005). One can evaluate r2 or q2 as he or she typically would with common regression
analysis; the higher the r2 (closer to 1.0) the better the prediction. Therefore, the q2 value
and its graph are a key aspect to evaluate the data generated in the CoMFA study.
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2.2.2

Criteria for “Robust” CoMFA Models

Molecular alignment plays a decisive role in CoMFA analysis, since the relative
interaction energies depend strongly on relative molecular positions; CoMFA then uses
statistical techniques for correlating several molecular features, such as steric and
electrostatic properties with their biological activities (Zhang et al., 2011). As mentioned
in Section 2.2.1, the “leave-one-out” process concerns cross-validation for the set of data
presented, essentially verifying what is often referred to as the “training set.” The
predictive q2 value refers to the internal robustness of the model (Zhang et al., 2011).
There is an understood minimum value for the q2 value of 0.3 to deem a QSAR model as
statistically significant (Jung et al., 2004; Park et al., 2009). In fact, Clark and Cramer
presented findings that virtually any q2 value greater than 0.25 from CoMFA can be
accepted as very unlikely to have resulted from chance correlation; however there is
some possibility that CoMFA and similar PLS-based approaches can overlook a “true”
correlation within a set of data (1993). With the interest of establishing criteria for robust
QSAR models, Tropsha and coworkers introduced a new validation criterion (Zhang et
al., 2011). Many authors consider high q2 (for instance, q2 > 0.5) as an indicator or even
as the ultimate proof that the model is highly predictive; however, the high q2 does not
imply automatically a high predictive ability of the model (Golbraikh and Tropsha,
2002). Golbraikh and Tropsha state that the use of an external set of compounds with
known experimental data, often referred to as the “test set,” for the model validation is
always necessary (2002). Further, the aforementioned validation criterion that was
developed by Golbraikh and colleagues is centered on test set criterion (Golbraikh et al.,
2002, 2003). Golbraikh and colleagues present that the satisfaction of Equations 2.5 - 2.9
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conclude that a QSAR model has acceptable predictive power (2002, 2003).

q2 > 0.5

(2.5)

R2 > 0.6

(2.6)

(R2 − R20 )
< 0.1 and 0.85 ≤ k ≤ 1.15
R2

(2.7)

or

(R2 − R′2
0)
< 0.1 and 0.85 ≤ k′ ≤ 1.15
R2

(2.8)

|R20 − R′2
0 | < 0.3

(2.9)

Note that R2 is the quantity characterizing linear regression (trendline) between the
predicted and observed activities while R20 is the quantity characterizing linear regression
with the Y-intercept set to zero (k represents the slope of that line as in Y = kX; R′2
0 is
the same as R20 but is related to observed vs predicted activities. k′ is the slope of Y = kx
for R′2
0 ) (Golbraikh et al., 2003). Additionally, Golbraikh and colleagues determined that
an external test set needs to have at least five compounds.
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2.3 Design of New Ligands
The development of pharmacophore models, CoMFA analysis, validation techniques and
collected observations about the molecular properties, all aforementioned, combine to
yield the design of new ligands with prediction of activities. CoMFA contour maps are
the key to understanding where the enhancement of electrostatic or steric properties
would benefit a molecule. Therefore, we can see the value in performing this research –
to eventually design new potential drug candidates for receptors, in this case for sigma 1
and 2 receptors.
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CHAPTER 3
MOLECULAR MODELING OF SIGMA 1 RECEPTOR LIGANDS

3.1 Introduction
Sigma receptors were originally and incorrectly characterized as a new subtype of opoid
receptors in the 1970s (Collina et al., 2007; Marriott et al., 2012). It has been clarified
that sigma receptors are different from opioid and N-methyl-D-aspartate (NMDA)
phenycyclidine receptors, that they bind numerous xenobiotics of unrelated compound
classes including clinical drugs used in psychiatric disorders, neurodegenerative
disorders, pain, amnesia and abuse drugs such as cocaine (Marriott et al., 2012). Ligand
binding experiments and biochemical analysis has differentiated the sigma 1 receptor
from sigma 2 receptor (Rack et al., 2011). The sigma 1 receptor has been cloned and is a
25.3 kDa membrane bound protein; the amino acid sequence does not show any
homology or similarity with any other known mammalian protein (Hanner et al., 1996,
Rack et al., 2011). Sigma 2 receptors are understood to be smaller in size than the sigma
1 receptor and that they do not translocate as the sigma 1 receptor does (Marriott et al.,
2012). There appears to be less information and knowledge of the sigma 2 receptor,
however its molecular weight has been approximated to be 21.5 kDa (Jasper et al., 2012).
Concerning the prominence of sigma 1 receptors, large amounts have been discovered in
various organs and tissues including the heart, liver, kidney and the eye including some
human tumor cell lines (Rack et al., 2011). The physiological function is still to be
completely understood beyond calcium channels and neurotransmitter modulation; there
is some agreement to consider its role more like an activator/inactivator as opposed to
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anagonist/antagonist (Cobos et al., 2008; Collina et al., 2007).
In the present study, several classes of sigma 1 ligands were selected. It was
desired to create a pharmacophore model for each class, compare the models, develop a
comprehensive pharmacophore that represents all of the selected sigma 1 classes and then
compare the comprehensive model with the findings previously determined by Gund and
colleagues. Additional analysis to include comparison to other models by researchers was
also pursued.
Gund and colleagues have developed several pharmacophore models through
various studies. The model developed in 1991 by Gund was originally compared with the
initial idea of Manallack and coworkers regarding hydrophobic and hydrophilic sites
(Gund et al., 1991; Jung et al., 2004; Manallack et al., 1988). The model in 1991 had
corresponding distances of 5.3-5.7 angstroms for N-C, 7.3-7.9 angstroms for C-lone pair
and 2.7-3.0 for N or C – lone pair (Gund et al., 1991). This model was further developed
by Jung, Floyd and Gund in 2004 with values for those distances, respectively, of 7.138,
8.662 and 2.508 angstroms. Note that Figure 3.2 presents that an additional
electronegative feature, the oxygen, as a feature of the pharmacophore model at that time.

Figure 3.1 Gund pharmacophore for sigma 1 receptor ligands.
Source: Gund et al., 1991.
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Figure 3.2 Gund pharmacophore for sigma 1 receptor ligands.
Source: Jung et al., 2004.

This study builds on the original Gund models from 1991 and 2003. The other
models, which vary from researcher to researcher, are explored and compared with the
new models generated in this study in Section 3.4.

3.2 Selection of Ligands
Fourty-four sigma 1 receptor ligands were selected for the present study – concerning
sigma 1 - based on an extensive literature search. Considerations for selection included
incorporating recently synthesized and researched ligands (from 2012 and 2013) that
showed properties of moderate to high affinity values calculated via competitive
radioligand binding studies using [3H](+)(-)pentazocine as a radioligand. Highly active
ligands previously studied by Gund and colleagues were also included as references.
Tacke and coworkers focused on a series of high-affinity, selective sigma ligands
of 1,2,3,4-tetrahydrospiro[naphthalene-1,4’piperidine] type along with related sigma
ligands of the 1,4’-silaspiro[indane-1,4’-piperidine] type (Tacke et al., 2012). Note that
silasubstitution was a key aspect of Tacke’s study to determine the effect of replacing the
carbon spirocenters with silicon atoms (Tacke et al., 2012). The corresponding molecules
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in these series are presented with their affinity data in Tables 3.1 and 3.2 for compounds
1-8.
Table 3.1 Binding and Functional Data of 1,2,3,4-tetrahydrospiro[naphthalene-1,4’piperidine] Series

σ1Ki(nM)

σ2Ki(nM)

σ2/ σ1

1*

2.0 ± 0.5

44 ± 21

22

2

3.8 ± 1.8

206 ± 71

54

3

8.0 ± 1.9

34 ± 4.7

4

4

1.8 ± 1.3

5.5 ± 1.5

3

Compound

R1 group

*Indicates included in the comprehensive sigma 1 pharmacophore derivation.
Source: Tacke et al., 2012.
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Table 3.2 Binding and Functional Data of 1,4’-silaspiro[indane-1,4’-piperidine] Series

σ1Ki(nM)

σ2Ki(nM)

σ2/ σ1

5

1.1 ± 0.5

243 ± 94

221

6

2.7 ± 0.5

460 ± 96

170

7

2.9 ± 0.8

39 ± 11.8

13

8

0.3 ± 0.2

19 ± 1.4

63

Compound

R1 group

Source: Tacke et al., 2012.

For compounds 9-14, Harel and colleagues combined the pharmacophoric
elements of potent sigma 1 ligands spirocyclic thienopyrans to result in aminoethyl
substituted tetrahydrobenzothiophenes (Harel et al., 2013). Though the resulting
molecules demonstrated a reduction in affinity (moderate to low), modeling this class,
particularly by overlaying the molecules, can teach us visually how closely the new
molecules overlay with the reference compounds when the pharmacophore is created.
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Further, we can learn from the work of Harel and coworkers that essentially increasing
the conformational flexibility of the aminoethyl side chain can explain the decrease in
affinity in this class (Harel, et al., 2013). These molecules and corresponding data are
shown in Tables 3.3 and 3.4.

Table 3.3 Binding and Functional Data of Spirocyclic Thienopyran System and
Aminoethyl-substituted Tetrahydrobenzothiophenes

Compound

R1 group

σ1Ki(nM)

σ2Ki(nM)

σ2/ σ1

9*

CH2Ph

0.31 ± 0.06

13 ± 2.5

42

10

CH2C6H11

0.66 ± 0.16

3.3 ± 0.3

5

*Indicates included in the comprehensive sigma 1 pharmacophore derivation.
Source: Harel et al., 2013.
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Table 3.4 Binding and Functional Data of Spirocyclic Thienopyran System and
Aminoethyl-substituted Tetrahydrobenzothiophenes

Compound

R1 group

σ1Ki(nM)

σ2Ki(nM)

σ2/ σ1

11

PhCH2

49 ± 2.0

149

3

12

PhCH2CH2

126 ± 73

129 ± 20

1

13

PhCH2CH2CH2

132

166

1

14

C6H11CH2

5.0 ± 2.0

10 ± 1.0

2

Source: Harel et al., 2013.

Compounds 15-17 were studied by Wang and colleagues (2013) to evaluate
potential radiotracers for imaging sigma 1 receptors with PET (Positron Emission
Topography). Interestingly, the lead compound, 1-(1,3-benzodioxol-5-ylmethyl)-4-94-92fluoroethoxy)benzyl)piperazine) does not exhibit the highest activity compared to other
compounds in this study (activity at 1.85 nM but comparable with references), however it
has been identified as a suitable radiotracer and therefore is worth studying as it does
have an impact for sigma-1 receptor-type applications (Wang et al., 2013). Compounds
16 and 17 were also studied as part of the series of fluoro-oligo-ethoxylated 4-
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benzylpiperazine derivatives as potential sigma 1 receptor ligands. These molecules and
corresponding data are shown in Table 3.5

Table 3.5 Binding and Functional Data of Fluoro-oligo-ethoxylated 4-benzylpiperazine
Derivatives

R1 group

σ1Ki(nM)

σ2Ki(nM)

σ2/ σ1

15*

F

1.85 ± 1.59

291 ±111

157

16

OCH2CH2F

40.7 ± 22.8

666 ± 106

16.4

17

OCH2CH2OCH2CH2F

505 ± 120

1420 ± 160

2.81

Compound

*Indicates included in the comprehensive sigma 1 pharmacophore derivation.
Source: Wang et al., 2013.

Compounds 18-38, spirocyclic thophenes, were studied by Meyer and coworkers
(2012). This group studied pharmacophore models from various papers for sigma 1 and
consequently tried to enlarge the lipophilic region of the thiophene moiety to achieve a
higher sigma 1 affinity (Meyer et al., 2012). The sigma 1 affinity of the phenylated
compounds is comparable or slightly reduced compared to the nonphenylated
compounds; the placement of the S-atom appears to be a key aspect impacting affinity in
this study, not necessarily increasing the lipophilicity of the thiophene moiety (Meyer et
al., 2012). The spirocyclic thiophenes studied have reasonable sigma 1 affinities and due
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to the focus of the impact of structural changes on the binding sites they are worth
studying; the corresponding data and molecules are in Table 3.6.
Table 3.6 Binding and Functional Data of Spirocyclic Thiophenes Series

18

19

21

22

24

20

23

25

Source: Meyer et al., 2012
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Table 3.6 (continued) Binding and Functional Data of Spirocyclic Thiophenes Series

27

28

29

30

31

32

33

34

35

36

37

38

Source: Meyer et al., 2012
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Table 3.6 (continued) Binding and Functional Data of Spirocyclic Thiophenes Series
Compound

σ1Ki(nM)

18

1.0 ± 0.30

19

1.9 ± 0.44

20

255

21

0.35 ± 0.06

22

0.22 ± 0.06

23

40 ± 13

24

0.32 ± 0.10

25

1.6 ± 0.70

26

5.4 ± 0.97

27

5.3 ± 0.88

28

2.4 ± 0.69

29

16 ± 5.8

30

23 ± 9.9

31

4.5 ± 2.9

32

1.0 ± 0.4

33

2.5 ± 0.91

34

5.5 ± 1.5

35

16 ± 6.8

36

11 ± 3.2

37

483

38

87 ± 52

Source: Meyer et al., 2012

22

Since we are building on the foundation of Gund and colleagues, it is appropriate
to use reference compounds from their work (Gund et al., 2004). Commonly researchers
use rigid compounds for the pharmacophore modeling to help serve as templates since
the rotatable bonds are more limited, reducing the number of potential conformers. In the
selection of reference compounds, some rigid molecules were considered such as
Spipethiane (43) and (+)-Pentazocine (44). An extremely highly active compound for
sigma 1, PD144418 (41) is also included, however it has many conformers/rotatable
bonds. The reference molecules included from Gund’s previous work are in Table 3.7.

Table 3.7 Binding and Functional Data of Reference Compounds

39

(+)3PPP

40

Source: Gund, et al., 2003.
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Haloperidol

Table 3.7 (continued) Binding and Functional Data of reference compounds

41

PD144418

42

PRE084

43

Spipethiane

44 (+) –Pentazocine

σ1Ki(nM)

σ2Ki(nM)

σ1/ σ2

39

23.7 ± 3.8

176.3 ± 23

7

(Jbilo et. al, 1997)

40

1.2 ± 0.20

26 ± 5.4

22

(Akunne et. al, 1997)

41*

0.08

1377

5.8 × 10-5

(Akunne et. al, 1997)

42

44

43*

0.5 ± 0.02

416 ± 43

0.0012

(Quaglia et al., 1998)

44*

5.8 ± 1.0

1253 ± 519

0.0046

(Akunne et. al, 1997)

Compound

(Su et. al, 1991)

*Indicates included in the comprehensive sigma 1 pharmacophore derivation.
Source: Gund, et al., 2003 (original data sources listed above as specified by Gund et al.).
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3.3 Materials and Methods
All molecules were initially drawn in Spartan ’14 and then optimized at the HF/6-31G*
and B3LYP/6-31G* levels prior to being imported into the SYBYL-X 2.1 program.
Molecular databases were created within SYBYL-X 2.1 to represent each class of
compounds for the sigma 1 receptor ligands. DISCOtech, a tool within SYBYL-X 2.1,
was then used to generate pharmacophores for each of the classes. Pharmacophore
development for each set of selected molecules was conducted by utilizing the options
within DISCOtech for feature selection (binding site), conformer searches, etc. to yield
potential pharmacophore models. Following the development of pharmacophore models
for each class, a database was created to include the most active/lead compounds with
some rigid references and active references from the previous work by Gund and
colleagues. This database was then utilized to develop a comprehensive pharmacophore
to represent all of the sigma 1 ligand classes studied in this work. Once pharmacophore
models were completed, the Comparative Molecular Field Analysis models were created
for the sigma 1 molecules calculated at HF/6-31G* and B3LYP/6-31G* levels,
respectively. New ligands were designed once the CoMFA models were determined to
meet robust criteria; contour maps generated from the CoMFA models were studied
during the new ligand design process. Additional information about the pharmacophore
derivation, CoMFA and design of new ligands are in Sections 3.4, 3.5, and 3.6,
respectively.
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3.4 Pharmacophore Derivation
DISCOtech allows the researcher to manually select the binding features of each
molecule to be considered for pharmacophore generation. For these classes, hydrophobic
groups, positive nitrogen, lone pair and aromatic groups (same as the hydrophobic groups
selected in these particular cases) were used. This was done via an iterative process. First,
models were explored without constraints or features selected, and gradually various
combinations of binding groups were included; eventually this iterative process yielded
the typical models, in terms of binding sites, that Gund and coworkers had developed
over the years (Jung et. al, 2004). Specifics regarding each class and the derivations are
discussed in Section 3.4.1.

3.4.1 Pharmacophore Models
Pharmacophores were generated using DISCOtech in SYBYL-X 2.1 for each class of
compounds and are shown as labelled in Figures 3.3 through 3.16 and Figures 3.19
through 3.21. As with the aforementioned Gund, Jung, Floyd models discussed (2003,
2004), the main binding sites are the nitrogen site, the lone pair of electrons and a
hydrophobic/aromatic group. The distances between these groups for the various classes
are on the order of the previous models which are in Figures 3.1 and 3.2; these models
are more extensively analyzed during the discussion later in this section concerning the
representative sigma 1 pharmacophore (Figures 3.19 – 3.21).
Figures 3.3 – 3.5 depict the model developed for the Tacke Series: 1,2,3,4tetrahydrospiro[naphthalene-1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine]
series (compounds 1-8). The distance from the N atom to the lone pair was 2.9 Å; from
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the center of the aromatic/hydrophobic ring (phenyl) to the N atom the distance was 5.08
Å; and the distance from the lone pair to the center of the aromatic/hydrophobic ring was
6.89 Å.

Figure 3.3 DISCOtech pharmacophore derivation and overlay of 1,2,3,4tetrahydrospiro[naphthalene-1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine]
series (compounds 1-8, hydrogen atoms hidden).

Figure
3.4
DISCOtech
pharmacophore
derivation
of
1,2,3,4tetrahydrospiro[naphthalene-1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine]
series (compounds 1-8) with lead compound 1, hydrogen atoms hidden.
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Figure 3.5 DISCOtech pharmacophore model of 1,2,3,4-tetrahydrospiro[naphthalene1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine] series (compounds 1-8). Purple
sphere = acceptor site, red sphere = positive nitrogen and green sphere =
aromatic/hydrophobic center.
Figures 3.6 – 3.8 depict the pharmacophore derivation of the spirocyclic thienopyran
system and aminoethyl-substituted tetrahydrobenzothiophenes (compounds 9-14). Note
that in this case, the aromatic/hydrophobic ring consists of a thiophene ring. The distance
from the N atom to the lone pair was 2.9 Å; from the center of the aromatic/hydrophobic
ring to the N atom the distance was 5.53 Å; and the distance from the lone pair to the
center of the aromatic/hydrophobic ring was 8.25 Å.
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Figure 3.6 DISCOtech pharmacophore derivation of spirocyclic thienopyran system and
aminoethyl-substituted tetrahydrobenzothiophenes (compounds 9-14, hydrogen atoms
hidden).

Figure 3.7 DISCOtech pharmacophore derivation of spirocyclic thienopyran system and
aminoethyl-substituted tetrahydrobenzothiophenes (compounds 9-14) with lead
compound 9, hydrogen atoms hidden.
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Figure 3.8 DISCOtech pharmacophore model of spirocyclic thienopyran system and
aminoethyl-substituted tetrahydrobenzothiophenes (compounds 9-14). Purple sphere =
acceptor site, red sphere = positive nitrogen and green sphere = aromatic/hydrophobic
center.
Figures 3.9 – 3.11 depict the pharmacophore derivation of the fluoro-oligoethoxylated 4-benzylpiperazine derivatives (compounds 15-17). Note that in this case,
the aromatic/hydrophobic ring consists of a phenyl ring. The distance from the N atom to
the lone pair was 2.9 Å; from the center of the aromatic/hydrophobic ring to the N atom
the distance was 5.91 Å; and the distance from the lone pair to the center of the
aromatic/hydrophobic ring was 7.07 Å.
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Figure 3.9 DISCOtech pharmacophore derivation of fluoro-oligo-ethoxylated 4benzylpiperazine derivatives (compounds 15-17, hydrogen atoms hidden).

Figure 3.10 DISCOtech pharmacophore derivation of fluoro-oligo-ethoxylated 4benzylpiperazine derivatives (compounds 15-17) with lead compound 15.
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Figure 3.11 DISCOtech pharmacophore model of fluoro-oligo-ethoxylated 4benzylpiperazine derivatives (compounds 15-17). Purple sphere = acceptor site, pink
sphere = positive nitrogen and yellow sphere = aromatic/hydrophobic center.

The model for the spirocyclic thiophenes (Figures 3.12 – 3.14) shows a distance
that is noticeably lower between the nitrogen and hydrophobic group as contrasted with
other class pharmacophore models; this could be due to difficulty experienced by the
researcher in directing DISCOtech to consider using the lipophilic groups Meyer and
coworkers discussed (2012). Poor overlay can be visually observed of the thiophene
moieties for the 21 spirocyclic thiophene molecules in Figure 3.12. The distance from
the N atom to the lone pair was 2.9 Å; from the center of the aromatic/hydrophobic ring
(phenyl) to the N atom the distance was 3.83 Å; and the distance from the lone pair to the
center of the aromatic/hydrophobic ring (phenyl) was 6.46 Å. It is important to note that
compound 22 from this class was used in the representative pharmacophore for sigma 1,
and in that pharmacophore the thiophene moiety was used by DISCOtech as opposed to
the phenyl ring as it is in the pharmacophore model in Figure 3.12. Therefore, an
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alternate pharmacophore model was explored for this class as shown in Figures 3.15 and
3.16, where the seven most highly active spirocyclic thiophene compounds were chosen
for the model (compounds 18, 19, 21, 22, 24, 25 and 32). This was a more inclusive
model depicting additional hydrophobic groups with the objective to confirm that the
thiophene moiety was a viable hydrophobic group for the pharmacophore as it occurred
in the representative pharmacophore for sigma 1. Indeed, as shown in Figure 3.16, a
pharmacophore model consisting of more than three points is possible for this class, and
the highlighted section with the thiophene moiety, in this case for the most highly active
ligand – compound 22 – is presented. In that case, the distance from the N atom to the
lone pair was 2.9 Å; from the center of the thiophene ring to the N atom the distance was
5.36 Å; and the distance from the lone pair to the center of the thiophene ring was 7.54 Å.
Therefore, it was determined that the spirocyclic thiophene class, depending on the
ligands chosen, could have additional hydrophobic groups as part of the model. When the
molecules were aligned with other molecules from other classes in CoMFA or used in the
representative pharmacophore, it was interesting to note that the thiophene moiety
aligned to the hydrophobic groups of the other molecules as opposed to the original
phenyl ring used in DISCOtech for the spirocyclic thiophene specific pharmacophore.
The features of the other molecules later used for the representative pharmacophore were
a key reason that the approach on the part of the researcher for this study did not include
other pharmacophoric features that other groups, such as Meyer coworkers, did in their
2012 work. Meyer and coworkers similarly used hydrophobic/aromatic points as well as
the nitrogen atom, however they included additional hydrophobic centers in their
molecule as pharmacophoric points which did not exist for every spirocyclic thiophene
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molecule in this study or theirs (the additional phenyl ring attached to the thiophene ring,
for instance) and also used donor atoms and corresponding acceptor sites outside of
nitrogen and its lone pair, which again, did not always exist for the other sigma 1 ligands
in our study (Meyer et al., 2012). Since the researcher in this study was aiming to develop
consistency in the class pharmacophores with an overall, representative pharmacophore
for sigma 1, features as seen in Figures 3.17 and 3.18 were not included. Work continues,
as stated by Gund et al., in accordance with the suggestion that one pharmacophore may
be sufficient to rationalize the binding of all sigma ligands (1992).
There seems to be agreement about the thiophene moiety being a viable binding
group point as well as the nitrogen atom with the additional possibility of the phenyl
group nearest the nitrogen atom being a hydrophobic/aromatic point; therefore these three
points from our Figure 3.16 agree with the Meyer model depicted in Figure 3.17. Again,
these models are more specific to spirocyclic thiophenes and are not necessarily
representative to the overall sigma 1 pharmacophore; the “triangle” effect does exist in
both the original and alternate spirocyclic thiopehene pharmacophores in Figures 3.14 or
Figure 3.16, with the difference in the hydrophobic/aromatic group being either the
phenyl ring or thiophene ring, respectively. A final point on the Meyer and coworkers’
model is that a different approach and software was used for their pharmacophore
modeling with the primary focus being spirocyclic thiophenes, specifically to explore the
hydrophobic binding region of the sigma 1 receptor protein (Meyer et al., 2012).
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Figure 3.12 DISCOtech pharmacophore derivation of spirocyclic thiophenes
(compounds 18-38, hydrogen atoms hidden).
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Figure 3.13 DISCOtech pharmacophore derivation of spirocyclic thiophenes
(compounds 18-38, hydrogen atoms hidden) with lead compound 18.

Figure 3.14 DISCOtech pharmacophore derivation of spirocyclic thiophenes
(compounds 18-38). Purple sphere = acceptor site, red sphere = positive nitrogen and
green sphere = aromatic/hydrophobic center.
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Figure 3.15 Alternate DISCOtech pharmacophore derivation of spirocyclic thiophenes
(highest activity compounds of series; hydrogen atoms hidden - compounds 18, 19, 21,
22, 24, 25 and 32).

Figure 3.16 Alternate DISCOtech pharmacophore derivation of spirocyclic thiophenes
with compound 22, hydrogen atoms hidden. Purple sphere = acceptor site, red sphere =
positive nitrogen and green sphere = aromatic/hydrophobic center. Additional sphere in
blue indicates a hydrophobic point. Highlight in yellow also depicts an alternate
“triangle” pharacophore.
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Figure 3.17 Meyer and coworkers’ mapping of compound “3b” (compound 32) onto a
3D pharmacophore model. Red sphere is the nitrogen/positive ionizable group, pink
sphere is hydrogen/aromatic group and hydrogen bond acceptor is light green denoted as
two spheres, the smaller being the location of the hydrogen bond acceptor on the ligand
and the larger one being the location of the hydrogen bond donor on the receptor.
Source: Meyer et al., 2012.

Figure 3.18 Distances for spirocyclic thiophene pharmacophore generated by Meyer
and coworkers. Red sphere = nitrogen, pink sphere = hydrogen/aromatic group and
hydrogen bond acceptor is light green denoted as two spheres, the smaller being the
location of the hydrogen bond acceptor on the ligand and the larger one being the
location of the hydrogen bond donor on the receptor).
Source: Meyer et al., 2012.

For the derivation of the sigma 1 representative pharmacophore as depicted in
Figures 3.19 – 3.21, seven highly active ligands were used. Reference compounds from
previous work in the Gund group included compound 43, Spipethiane (rigid), compound
44, (+)-Pentazocine (rigid) and compound 41, PD144418 (most active sigma 1 ligand
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identified). The molecules additionally chosen from the new classes studied in this work
for the representative pharmacophore included: compound 1 (lead compound for 1,2,3,4tetrahydrospiro[naphthalene-1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine]
series), compound 9 (lead compound for spirocyclic thienopyran system and aminoethylsubstituted tetrahydrobenzothiophenes), compound 15 (lead compound for fluoro-oligoethoxylated 4-benzylpiperazine derivatives) and compound 22 (highest activity
spirocyclic thiophene molecule in this study). Spipethiane (compound 43)

was

designated as the reference molecule in DISCOtech since it was a rigid yet second
highest active sigma 1 ligand of the compounds chosen. The resulting pharmacophore
included the typical features aforementioned – the lone pair of electrons, the nitrogen
atom and the center of a hydrophobic/aromatic ring. The distance from the N atom to the
lone pair was 2.9 Å; from the center of the hydrophobic ring (varied from phenyl ring to
thiophene ring depending on the molecule) to the N atom the distance was 6.80 Å; and
the distance from the lone pair to the center of the thiophene ring was 8.45 Å. The last
sigma 1 model from the Gund group in 2003 had proposed the pharmacophore to have
similar distances for the same binding features. Therefore, the current model shows 8.45
Å vs 8.662 Å (previous model) for C-lone pair; 6.80 Å vs 7.135 Å (previous model) and
2.90 Å vs 2.508 Å (previous model) (Jung et al., 2004). The previous model in 2004 had
used three main classes in addition to references. The three main classes were
Spipethiane and its analogs, Piperidine and Piperazine Analogs and Benzothiazolone
Analogs along with other ligands including PD144418 (Jung et al., 2004). The
importance of the current work is that it essentially takes elements of the work in 1991
and 2004 and expands it to include more recent data on other sigma 1 ligands such as the
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1,2,3,4-tetrahydrospiro[naphthalene-1,4’-piperidine]

and

piperidine] series, spirocyclic thienopyran system and

1,4’-silaspiro[indane-1,4’aminoethyl-substituted

tetrahydrobenzothiophenes and spirocyclic thiophene. The current model therefore
continues to promote the idea of the original 1991 model of the “triangle” shaped
pharmacophore, retaining the idea of the importance of the lone pair as an aspect of the
model; the oxygen atom, though an element in some of the molecules studied and
previously presented as an important aspect of previous pharmacophore models, is not
part of the pharmacophore model created in this current study.

Figure 3.19 Comprehensive DISCOtech pharmacophore derivation representing entire
Sigma 1 class of molecules studied (hydrogen atoms hidden – compounds 1, 9, 15, 22,
41, 43 and 44).
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Figure 3.20 Comprehensive DISCOtech pharmacophore derivation for Sigma 1. Purple
sphere = acceptor site, red sphere = positive nitrogen and green sphere =
aromatic/hydrophobic center.

Certainly there is consistency, particularly with the aforementioned “triangle”
shape in terms of distances and the main binding groups of the lone pair, nitrogen atom
and center of a hydrophobic ring, in the pharmacophore modeling by the Gund group as
the classes of sigma 1 compounds increased significantly over the years. Other
researchers have proposed pharmacophore models as well for sigma 1 ligands; most of
the other models developed have been designed by researchers who have synthesized
sigma 1 ligands and therefore want to understand the relationship of the activities
generated with the molecular structure of the synthesized molecules. Laggner and
coworkers presented their pharmacophore model in Figure 3.22 featuring nitrogen and
the phenyl group as important binding sites, however the additional hydrophobic groups
featured are not in agreement in our model (2005). Though the additional hydrophobic
features can be recognized in many of the molecules in this study, our model includes a
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feature that Laggner’s model does not have – that of the lone pair of electrons as seen in
Figure 3.21. Note that the researcher did change the feature selection in DISCOtech in
this study to simulate some of the other models for comparison and educational purposes.
For instance, DISCOtech could not simulate Laggner’s model because the representative
sigma 1 ligands did not all have 4 hydrophobic features available, demonstrating that
pharmacophore models can be very dependent on the molecules chosen. Instead, a
modified version of Laggner’s pharmacophore was created while including the additional
feature of the lone pair of electrons as seen in Figure 3.24, however this model is not the
leading or preferred model of the researcher since it does not represent the alignment
approach later used for the Comparative Molecular Field Analysis (ComFA). The
CoMFA, described in detail in Section 3.5, had the tightest alignment by approaching a
fit primarily around the nitrogen atom and surrounding atoms (in an attempt to overlay
the acceptor site and the N atoms of all of the molecules) while simultaneously trying to
overlay the thiophene or phenyl moieties in the same binding site as the pharmacophore
in Figure 3.19. Note that most other researchers do not show diagrams of how their
molecules overlay; though supplemental data is available to address tolerances and
distances for the binding groups, visually one cannot observe how the cyclohexyl (or N
and surrounding atoms) align, specifically directionally. Our CoMFA and pharmacophore
models align directionally for the cyclohexyl ring, with the objective for the lone pairs to
overlap. Since the CoMFA models conducted in Section 3.5 are considered “robust” and
highly predictive based on peer-reviewed journal criteria, the researcher for this study
therefore postulates that the representative pharmacophore in Figure 3.19 is a key
pharmacophore model for sigma 1 ligands since its inherent structure was used as a basis
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for the successful CoMFA models.
Figure 3.23 depicts another pharmacophore model, in this case by Collina et al.
(2007). Similar to Laggner’s model in Figure 3.22, this model is depicting nitrogen as a
positive ionizable feature with the remaining three features being hydrophobic binding
sites.
For completeness, additional DISCOtech iterations were considered to include
additional hydrophobic groups since other researchers included them. The model that is
most similar to our lead pharmacophore from Figure 3.19 is in Figure 3.25 where an
additional hydrophobic group (near the aromatic/primary hydrophobic groups as
postulated by other researchers) is shown. This model, however, does not visually appear
to align as closely for the thiophene/phenyl rings for the aromatic/hydrophobic binding
site.
Literature often cites the Glennon model shown in Figure 3.23 (2005). This model
was recreated in DISCOtech as seen in Figure 3.27 with similar distances; the N atom to
the primary hydrophobic region being 6.8 Å, consistent with the Glennon range of 6-10 Å
as well as the N to secondary hydrophobic region being 3.72 Å, consistent with the
Glennon range of 2.5-3.9 Å. Glennon is another researcher who does not include the
concept of the lone pair of electrons in his model. If the model is forced to include it, as
shown in Figure 3.28, the distances between the primary hydrophobic region and the N
atom reduces to 4.54 Å.
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Figure 3.21 Comprehensive DISCOtech pharmacophore derivation with reference
compound 43, Spipethiane.

Figure 3.22 Sigma 1 pharmacophore model for Laggner and coworkers.
Source: Laggner et al., 2005.
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Figure 3.23 Pharmacophore model for Collina and coworkers. Molecules 2 and 12 were
newly designed and synthesized in arylalkyl and alkenylamines series. Red sphere is
nitrogen/positive ionizable feature while the cyan spheres are hydrophobic features.
Source: Collina et al., 2007.

Figure 3.24 Alternate sigma 1 pharmacophore model with additional hydrophobic groups
(green spheres) to compare with Laggner et al. model. Pink sphere is N atom and purple
sphere is lone pair of electrons.
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Figure 3.25 Additional alternate sigma 1 pharmacophore model with additional
hydrophobic group (green sphere) to compare with Laggner et al. model. Pink sphere is N
atom and purple sphere is lone pair of electrons.

Figure 3.26 Sigma 1 pharmacophore model for Glennon.
Source: Glennon, 2005.
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Figure 3.27 Additional alternate sigma 1 pharmacophore model without lone pair of
electrons to compare with the Glennon model. Pink sphere is N atom and green spheres
are hydrophobic groups

Figure 3.28 Additional alternate sigma 1 pharmacophore model with lone pair of
electrons to compare with Glennon model. Pink sphere is N atom and green spheres are
hydrophobic groups Lone pair is included as purple sphere.

The last pharmacophore model analyzed in this work was from Caballero et al.
(2012). In this case, Cabellero and colleagues had modeled methyl 2-(aminomethyl)-1-

47

phenylcyclopropane-1-carboxylate (MAPCC) derivatives, resulting in a pharmacophore
model as shown as “c” in Figure 3.29. Note the comparison between that model and the
aforementioned Glennon and Laggner models shown as (a) and (b) in the Figure 3.29,
respectively (Cabellero et al., 2012). Cabellero’s model differs from the Gund, Laggner
and Glennon models due to additional acceptor sites; this can mainly be attributed to the
fact that the structure is unique, particularly with the additional O atoms. The visual
molecule overlay for their pharmacophore was presented in their paper as well, however,
these molecules only had minor differences in terms of substituents and therefore the
conformations in their GALAHAD pharmacophore model molecules did not appear to
alter much as can be observed visually in Figure 3.30. Therefore, the researcher for this
study assumed that this pharmacophore is very specific for the MAPCC derivatives class
and does not represent a possible comprehensive sigma 1 pharmacophore.
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Figure 3.29 Caballero and coworkers’ figure depicting comparisons between Glennon
(a), Laggner (b) and their work (c). H1 and H2 are hydrophobic groups. N1 is Nitrogen.
A1, A2 and A3 are all acceptor groups.
Source: Caballero et al., 2012.

Figure 3.30 Caballero and coworkers’ GALAHAD pharmacophore model of MAPCC
derivatives and molecular alignment of the compounds. Cyan spheres are hydrophobic
points; red is positive nitrogen and green spheres are acceptor points.
Source: Caballero et al., 2012.

In summary, pharmacophore models were derived by the researcher for the
classes studied in this work. Additionally a representative pharmacophore was designed
and applied in the alignment techniques discussed in the CoMFA in Section 3.5. Again,
due to the success of the CoMFA using the pharmacophore in Figure 3.19 (which focuses
on the lone pair, hydrophobic/aromatic group and the N atom) and also due to the
aforementioned differences noted in the molecules and pharmacophore approaches
chosen by the other researchers, the leading, comprehensive model proposed by this
study remains to be the postulated model as depicted in Figures 3.19 – 3.21. As an
additional key point, Spipethiane (compound 43) was used as the reference for all of the
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representative pharmacophore models for sigma 1 and Spipethiane was consistently
applied as the template/reference molecule in the alignments for the CoMFA studies in
Section 3.5.

3.5 Comparative Molecular Field Analysis
3.5.1 Geometry Optimization and Electrostatic Studies
Each molecule in this study was optimized and saved at the ab initio HF/6-31G* and
density functional B3LYP/6-31G* levels with electrostatic charges. Once each molecule
was optimized, it was saved as a “.mol2” file with “electrostatic” to carry the
corresponding geometry and calculated electrostatic charges into SYBYL-X 2.1.

3.5.2 Alignment
Alignment of the HF/6-31G* and B3LYP/6-31G* optimized geometries for the sigma 1
ligands was an essential step in generating a CoMFA model for each calculation level,
respectively. A key point is that this was a rigid alignment approach with the intent to
maintain the bound conformation of each molecule at the calculation level being studied.
Many researchers, however, use flexible alignment approaches; as an example, Caballero
and researchers state that their 3D-QSAR models rely on the arbitrary alignment of
conformationally flexible ligands (2012). Since part of the objective of this study was to
observe the results, comparing ab initio with density functional methods, and also since
the conformation is unknown for each molecule when it binds to the sigma 1 receptor, the
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assumption was made that the energy should be minimized. Therefore the ab initio and
density functional methods calculated energy minimized geometries while also
calculating the electrostatic charges. The resulting molecules were then rigidly aligned to
each other.
The approach to alignment for the sigma 1 ligands consisted of matching up the N
atom and surrounding items, particularly those of the cyclohexyl ring, and matching up
the phenyl/thiophene (hydrophobic ring) moieties with the objective being to bind the
molecules together at the pharmacophore binding groups as seen in Figures 3.19 –
Figures 3.21. Spipethiane was the reference molecule used for the pharmacophore model
and therefore was the template molecule used to drive the alignment process. Since 28 of
the molecules in the data set that had similar geometry (cyclohexane ring), they were
initially matched to Spipethiane as the template using the “DISTILL RIGID” alignment
tool. The remaining molecules in the various classes were then manually aligned using
the “match atoms” feature; Spipethiane was first used as the template to match with the
lead compounds for the remaining series. Then the remaining molecules of those classes
were aligned to the lead compounds. Finally, the spirocyclic thiophene series was
removed from the whole database and was manually aligned at the thiphene moieties and
at the N and surrounding atoms to ensure a tighter alignment; then it was reintroduced
back to the database. Note that the researcher determined it was appropriate to leave out
the fluoro-oligo-ethoxylated 4-benzylpiperazine derivatives. Though the most active
ligand from that series remains in the pharmacophore, the series, perhaps due to
extremely different geometry/length and very varied activities (1.85 to 505 nM)
challenged the CoMFA models in robustness. Therefore, it was determined that this

51

series could perhaps instead be studied separately in the future and should be left out of
the CoMFA model; this is not uncommon in the area of QSAR, as other researchers have
similarly left out compounds when approaching rigorous modeling as seen by Dessalew
and colleagues for aminothiazole derivatives (Dessalew et al., 2007). The resulting
alignment for the sigma 1 ligands therefore consisted of 41 total sigma 1 molecules from
all of the other classes and reference molecules described. Consistent with the robust
criteria described in Section 2.2, 5 molecules were chosen as the test set with the
remaining 36 molecules acting as the training set. Additional details are provided in
Section 3.5.3. The final alignment of all 41 molecules can be viewed in Figure 3.31 for
HF/6-31G* and Figure 3.32 for B3LYP/6-31G*. The resulting alignments led to robust
models as described in Section 2.2.2. Additional details about the CoMFA models are
described in Section 3.5.3.
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Figure 3.31

Alignment of all 41 sigma 1 ligands at the HF/6-31G* calculation level.

Figure 3.32
level.

Alignment of all 41 sigma 1 ligands at the B3LYP/6-31G* calculation
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3.5.3 Quantitative Structure Activity Data Analysis
The CoMFA models were initiated by first conducting the molecular alignment as
described in Section 3.5.2. Each activity (Ki) value was converted to a pKi value using
Equation 2.4. The training set for the CoMFA ensured a range of at least 3 log units in
terms of pKi, as is suggested in the field and demonstrated by other researchers (Bolden
et al., 2013). The training set ranged from -2.6839 to 1.0969 whereas the test set ranged
from -1.6021 to 0.1805 log units. The histograms of the pKi vs number of molecules are
shown in Figures 3.33A and 3.33B.

Figure 3.33A Histogram of frequency vs pKi for sigma 1 ligands in training set.
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Figure 3.33B Histogram of frequency vs pKi for sigma 1 ligands in test set.
The CoMFA models were constructed using the default settings in SYBYL-X 2.1.
Therefore, an sp3 hybridized carbon atom was probed with a +1.0 unit charge which
extended at least 4 Å beyond each molecule, 2.0 Å grid spacing and the default 30
kcal/mol energy cutoff for steric and electrostatic fields. The CoMFA column, combined
with the literature pKi values, generated the Partial Least Squares cross-validated q2 for
each set, resulting in a predicted bioactivity (pKi) value for each training set molecule.
The test set, molecules which were not used to create the model, was used to validate the
model by comparing predicted bioactivities generated with the experimental results. The
resulting sigma 1 dataset at HF/6-31G* with 36 molecules in the training set resulted in a
q2 value of 0.505; the predicted bioactivity values for that set is in Table 3.8. The
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resulting sigma 1 dataset at B3LYP/6-31G* with 36 molecules in the training set resulted
in a q2 value of 0.575; the predicted bioactivity values for that set is in Table 3.8. The
results for the test set are in Table 3.9.
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Table 3.8
Experimental and Predicted Bioactivities (pKi) by the Training Set of
Sigma 1 Compounds using ab initio and Density Functional Calculation Methods
Compounds

Lit. pKi

HF/6-31G*

B3LYP/6-31G*
Predicted pKi

1

-0.301

-0.2581

-0.1822

2

-0.5798

-0.6452

-0.6272

3

-0.9031

-0.9516

-0.6721

4

-0.2553

-0.0579

-0.0921

5

-0.0414

0.0237

0.2759

6

-0.4314

-0.428

-0.3173

8

0.5229

0.3211

0.1738

9

0.5086

0.4623

0.5991

11

-1.6902

-1.5966

-1.3458

12

-2.1004

-1.9396

-1.7909

13

-2.1206

-2.0014

-2.09

14

-0.699

-1.0236

-1.0851

18

0

-0.332

-0.3653

19

-0.2788

-0.3033

-0.1645

20

-2.4065

-2.2125

-1.8888

21

0.4559

0.667

0.4532

22

0.6576

0.6577

0.5779

24

0.4949

0.5553

0.4325

25

-0.2041

-0.1467

-0.2289

26

-0.7324

-0.5731

-0.8959

27

-0.7243

-0.8645

-0.8959

28

-0.3802

-0.562

-0.7165

29

-1.2041

-0.9826

-1.0873

30

-1.3617

-1.4219

-1.3089

31

-0.6532

0.0019

-0.3292

32

0

-0.2851

-0.4657

33

-0.3979

-0.5994

-0.5278

35

-1.2041

-1.2222

-1.3218

36

-1.0414

-1.0603

-0.8683

37

-2.6839

-2.6033

-2.7247

38

-1.9395

-1.7999

-2.2428

39

-1.3747

-1.6467

-1.4024

41

1.0969

1.096

1.2858

42

-1.6435

-1.7795

-1.7619

43

0.301

0.2767

0.1636

44

-0.7634

-0.8428

-0.9157

57

Table 3.9
Experimental and Predicted Bioactivities (pKi) by the Test Set of Five
Sigma 1 Compounds using ab initio and Density Functional Calculation Methods
Compounds

Lit. pKi

HF/6-31G*

B3LYP/6-31G*
Predicted pKi

3

-0.4624

-0.5672

-0.3821

10

0.1805

0.2109

-0.3535

23

-1.6021

-1.6747

-1.5586

34

-0.7404

-0.7629

-0.9589

40

-0.0792

0.6129

0.2104

The Partial Least Squares Analysis (PLS), as described in Section 2.2.1, was used
by applying the SAMPLS algorithm in SYBYL-X 2.1 developed by Bruce Bush. The
optimum number of components was determined by the SYBYL-X 2.1 in the output
report from the SAMPLS algorithm and is shown in bold in Table 3.10. The number of
optimal components identified in the report was then applied without cross-validation
yielding the results in Table 3.11. The R2 values for HF/6-31G* and B3LYP/6-31G*
without cross-validation, using the optimal number of components for each, respectively,
at 5 and 4 yielded 0.959 and 0.938. Note that Table 3.11 also presents the electrostatic
and steric contributions to the CoMFA field.
Table 3.10
Optimal Component Number and q2 by “Leave-One-Out” using SAMPLS
by the Training Set of 36 Molecules

Lev.

Term

C. 1

C. 2

C. 3

C. 4

C. 5

C. 6

C. 7

C. 8

C. 9

C. 10

HF

s.e.e.

0.765

0.715

0.702

0.707

0.704

0.717

0.733

0.746

0.768

0.805

0.338

0.438

0.474

0.484

0.505

0.504

0.499

0.499

0.489

0.461

0.713

0.660

0.641

0.642

0.658

0.690

0.701

0.723

0.749

0.763

0.425

0.522

0.563

0.575

0.568

0.541

0.542

0.530

0.515

0.515

q
B3

2

s.e.e.
q

2

s.e.e. is standard error of estimates.
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Table 3.11
QSAR Reports by Non-Crossvalidation Using SAMPLS by the Training
Set of 36 Molecules
Calculation
Level

S.E.E.

R2

F Values

Steric.

Electro.

0.203
0.246

0.959
0.938

(n1 = 5, n2 = 30) 139.468
(n1 = 4, n2 = 31) 116.722

0.381
0.392

0.619
0.608

HF/6-31G*
B3LYP/6-31G*

s.e.e. is standard error of estimates.

The application of the robust criteria as described in Section 2.2.3 is shown in Figures
3.34 and 3.35 for HF/6-31G* in the graphs of predicted pKi values vs experimental pKi
values. The training set and tests were subject to Equations 2.5 – 2.9; those equations
were used to calculate and confirm that the HF/6-31G* CoMFA model meets the robust
criteria as defined by Golbraikh and colleagues in Table 3.12A (2002, 2003).

2.00

Training set:
y = 0.9582x - 0.028
R² = 0.9582

1.50
Test set:
y = 1.2176x + 0.2222
R² = 0.8893

1.00

Predicted pKi

0.50
0.00

y = 1.0392x
R0² = 0.8453

-0.50

Test
Training

-1.00

Linear (Training)

-1.50
-2.00
-2.50
-3.00
-3

-2

-1

0

1

2

Experimental pKi

Figure 3.34
HF/6-31G*.

Graph of Predicted pKi vs Experimental pKi by the CoMFA model at
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2.00
1.50
1.00
y = 0.8477x
R0'² = 0.7896

Experimental pKi

0.50
0.00
-0.50

Test

-1.00

Linear (Test)

-1.50
-2.00
-2.50
-3.00
-3

-2

-1

0

1

2

Predicted pKi

Figure 3.35 Graph of Experimental pKi vs Predicted pKi for Test Set by the CoMFA
model at HF/6-31G*.

Table 3.12A Results for QSAR Robust Criteria Equations 2.5 – 2.9 for HF/6-31G*
(Sigma 1)

(R2 −R20 )
R2

Equations (2.5 – 2.9)

Value

q2 > 0.5

q2 = 0.505

R2 > 0.6

R2 = 0.89
(R2 −R20 )

< 0.1 and 0.85 ≤ k ≤ 1.15

R2

|R20 − R′2
0 | < 0.3

= 0.05 and 𝑘 = 1.04

|R20 − R′2
0 | = 0.06

The application of the robust criteria as described in Section 2.2.3 is shown in Figures
3.36 and 3.37 for B3LYP/6-31G* in the graphs of predicted pKi values vs experimental
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pKi values. The training set and tests were subject to Equations 2.5 – 2.9; those equations
were used to calculate and confirm that the B3LYP/6-31G* CoMFA model meets the
robust criteria as defined by Golbraikh and colleagues in Table 3.12B (2002, 2003).

2.00

Training set:

1.50

Test set:
y = 0.87x - 0.1381
R² = 0.796

1.00

y = 0.9383x - 0.0491
R² = 0.9372

Predicted pki

0.50

y = 0.9809x
R0² = 0.766

0.00
-0.50

Test

-1.00

Training

-1.50

Linear (Training)

-2.00

-2.50
-3.00
-3

-2

-1

0

1

2

Experimental pKi

Figure 3.36 Graph of Predicted pKi vs Experimental pKi by the CoMFA model at
B3LYP/6-31G*.
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2.00
1.50
1.00
Experimental pKi

0.50

y = 0.9015x
R0'² = 0.7956

0.00
-0.50

Test

-1.00

Linear (Test)

-1.50
-2.00
-2.50
-3.00
-3

-2

-1

0

1

2

Predicted pKi

Figure 3.37 Graph of Experimental pKi vs Predicted pKi for Test Set by the CoMFA
model at B3LYP/6-31G*.
Table 3.12B Results for QSAR Robust Criteria Equations 2.5 – 2.9 for B3LYP/6-31G*
(Sigma 1)

(R2 −R20 )
R2

Equations (2.5 – 2.9)

Value

q2 > 0.5

q2 = 0.575

R2 > 0.6

R2 = 0.80
(R2 −R20 )

< 0.1 and 0.85 ≤ k ≤ 1.15

R2

|R20 − R′2
0 | < 0.3

= 0.04 and 𝑘 = 0.981

|R20 − R′2
0 | = 0.03

In summary, the bioactivity prediction for both models at HF/6-31G* and B3LYP/631G* were considered robust via PLS and the criteria set by Golbraikh and colleagues
(2002, 2003). Therefore, the model can serve as a means to predict other compounds for
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sigma 1 activity.

3.5.4 Contour Maps of CoMFA Models
Contour maps from the CoMFA models were explored with the objective to understand
the desired sterics and electrostatics that could enhance the activity of a molecule,
enabling the design of new ligands. In the maps, green represents steric bulk desirable
whereas yellow represents steric bulk undesirable. In terms of electrostatics, the maps
depict red for negative charge desirable whereas blue represents positive charge as
desirable. The differences observed in the CoMFA contour maps between HF/6-31G*
and B3LYP/6-31G* were also explored.
Figure 3.38 and Figure 3.39 show the contour maps for compound 43,
Spipethiane, which served as the reference molecule for pharmacophore generation as
well as the template molecule for the CoMFA alignment. Note that the steric bulk
desirable is consistent for the phenyl ring on the right and the left for both calculation
levels, however, there is some difference regarding bulk above and below the center of
the molecule. In terms of electrostatics, negative charge was consistently desirable over
the left phenyl ring, however positive charge did not display consistently between the two
calculation levels for the maps.
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Figure 3.38 Contour map of compound 43 (Spipethiane) at HF/6-31G*.

Figure 3.39 Contour map of compound 43 (Spipethiane) at B3LYP/6-31G*.

Figure 3.40 and Figure 3.41 show the contour maps for compound 41, PD144418,
the most active sigma 1 ligand in this study. Similar to the contour maps for Spipethiane,
the steric bulk desirable is consistent for the phenyl ring on the left for both calculation
levels; it is also consistent on the right side with the CH2 groups. There is some
difference regarding bulk above and below the center of the molecule. In terms of
electrostatics, negative charge was consistently desirable over the left phenyl ring,
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however, positive charge did not display consistently between the two calculation levels
for the maps.

Figure 3.40 Contour map of compound 41 (PD144418) at HF/6-31G*.

Figure 3.41 Contour map of compound 41 (PD144418) at B3LYP/6-31G*.

Additional contour maps showing the contour maps of the lead compounds can be found
in the APPENDIX.
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3.6 Design of New Sigma 1 Ligands

Utilizing the analysis conducted in Section 3.5.4, the design of new ligands was
conducted on compound 43, Spipethiane and compound 41, PD144418. The contour
maps showed that the area over the phenyl ring (left of the area with the S atom as seen
in Figures 3.38 and 3.39 – considered to be R1) had more bulk desirable, however it
depicts a slim profile for bulk. It also shows that the same area had negative charge
desirable. Therefore, various combinations were tried to meet the profile for bulk over
the phenyl ring while altering the electronegativity. Additionally, the phenyl ring on the
right side in Figures 3.38 and 3.39 showed a clear bulk desirable area – considered to be
R2 - and therefore, a tertiary butyl group was also tried for that area. The predicted
activities are shown in Table 3.13. The highest predicted activity increase consisted of:
0.2767 to 0.9242 at HF/6-31G* and 0.1636 to 0.7971 at B3LYP/6-31G* (literature
value at 0.301). Additionally, electronegative groups added in the R1 position such as
COOH, F and Cl, with H as the R2, improved bioactivity. A tertiary butyl group as the
R2 with H as the R1 also improved bioactivity. Note that low Ki values are desirable as
they represent high bioactivity (less compound to create an effect), however when the
Ki values are converted to pKi values then high pKi values are most desirable as they
mean high bioactivity (low pKi values represent low activity). The contour maps related
to the combinations of R groups shown in Table 3.13 are in Figures 3.42 – 3.59.
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Table 3.13: Spipethiane-based New Ligands

Compounds

R1

R2

Lit. pKi

HF/6-31G*

B3LYP/6-31G*
Predicted pKi

43

H

H

0.301

0.2767

0.1636

45

H

N/A

-0.2077

-0.1841

46

H

N/A

-0.0808

-0.2361

47

CH3

H

N/A

-0.0682

-0.1227

48

Cl

H

N/A

0.4989

0.303

H

N/A

0.7345

0.6057

49

50

F

H

N/A

0.6274

0.4738

51

I

H

N/A

0.2085

0.0463

tbutyl

N/A

0.9242

0.7971

tbutyl

N/A

0.4608

0.3224

52

53

H
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In Figures 3.42 and 3.43 a phenyl ring with a fluorine attached (to help the
electronegativity) was added as the R1 group. The R1 group overlapped into the yellow
undesirable area, perhaps the reason the bioactivity did not improve for this case.

Figure 3.42 Contour map of compound 45 at HF/6-31G*.

Figure 3.43 Contour map of compound 45 at B3LYP/6-31G*.

In Figures 3.44 and 3.45 a phenyl ring was added to explore adding bulk as R1 without
the influence of fluorine; the activity did not improve, perhaps because the R1 group
overlapped

into

the

undesirable

bulk
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area

of

the

contour

map.

Figure 3.44 Contour map of compound 46 at HF/6-31G*.

Figure 3.45 Contour map of compound 46 at B3LYP/6-31G*.

In Figures 3.46 and 3.47 a methyl group was added as R1 with the intent to better fit the
desirable bulk profile; even though the methyl group did not overlap into the undesirable
bulk area of the contour map in the HF/6-31G*, there was no benefit to adding it in terms
of bioactivity.
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Figure 3.46 Contour map of compound 47 at HF/6-31G*.

Figure 3.47 Contour map of compound 47 at B3LYP/6-31G*.
In Figures 3.48 and 3.49, chlorine was added as the R1 substituent. The overlap into the
desirable negative charge area can be observed on the map and perhaps explains the
improved bioactivity values of 0.4989 and 0.303 (from 0.2767 and 0.1636) at HF/6-31G*
and B3LYP/6-31G*, respectively.
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Figure 3.48 Contour map of compound 48 at HF/6-31G*.

Figure 3.49 Contour map of compound 48 at B3LYP/6-31G*.
In Figures 3.50 and 3.51, COOH was added as the R1 substituent. The overlap into the
desirable negative charge area can be observed on the map and perhaps explains the
improved bioactivity values of 0.7345 and 0.6057 (from 0.2767 and 0.1636) at HF/631G* and B3LYP/6-31G*, respectively.
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Figure 3.50 Contour map of compound 49 at HF/6-31G*.

Figure 3.51 Contour map of compound 49 at B3LYP/6-31G*.
In Figures 3.52 and 3.53, F was added as the R1 substituent. The overlap into the
desirable negative charge area can be observed on the map and perhaps explains the
improved bioactivity values of 0.6274 and 0.4738 (from 0.2767 and 0.1636) at HF/631G* and B3LYP/6-31G*, respectively.
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Figure 3.52 Contour map of compound 50 at HF/6-31G*.

Figure 3.53 Contour map of compound 50 at B3LYP/6-31G*.
In Figures 3.54 and 3.55, I was added as the R1 substituent. The bioactivity did not
improve for this case at either calculation level.
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Figure 3.54 Contour map of compound 51 at HF/6-31G*.

Figure 3.55 Contour map of compound 51 at B3LYP/6-31G*.

As aforementioned, there was successful minimization with increased activity by adding
electronegative substituents or groups such as COOH at the R1 spot and adding a tertiary
butyl (tbutyl) group to the R2 spot. In fact, for Spipethiane, this combination, shown in
Figures 3.56 and 3.57, resulted in the most highly active new ligand according to both the
HF/6-31G* and B3LYP/6-31G* CoMFA models at 0.9242 and 0.7971 pKi values,
respectively, essentially meaning a possible value of 0.119 nM when the 0.9242 value is
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converted. This data is useful as it shows that Spipethiane, which is more rigid than the
most active sigma 1 ligand identified, PD144418 could potentially have close to the same
activity, where PD144418 currently measures at 0.08 nM. PD144418 as a basis for new
ligands was also explored to determine if there are possibilities to increase the value of
0.08nM (1.0969 pKi) as seen in Table 3.14.

Figure 3.56 Contour map of compound 52 at HF/6-31G*.

Figure 3.57 Contour map of compound 52 at B3LYP/6-31G*.

Continuing to apply tbutyl as an R2 group, but without an R1 group (using hydrogen
instead), the activity is still higher than predicted for the original molecule by both
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models but is not as effective as when having an R1 group such as COOH. Consequently
the pKi values were 0.4608 and 0.3224 for HF/6-31G* and B3LYP/6-31G*, respectively.
The corresponding contour maps for tbutyl as an R2 group only are in Figures 3.58 and
3.59.

Figure 3.58 Contour map of compound 53 at HF/6-31G*.

Figure 3.59 Contour map of compound 53 at B3LYP/6-31G*.

The design of new ligands around Spipethiane led to findings mentioned above;
therefore, design of new ligands also occurred with PD144418, the most highly active
sigma 1 ligand, to determine if there is the possibility that it could be even more active.
Table 3.14 demonstrates that the addition of electronegative substituents or groups such
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as F, Cl and COOH can help improve the bioactivity of PD144418 but that the addition
of bulk, in either R, R1 or R2 (Table 3.14 and Table 3.15), did not help. Part of this could
be due to the fact that since PD144418 is more flexible than Spipethiane; when the
molecule would minimize at the calculation levels the substituents would not always
appear in the expected location from the way it was designed. The highest predicted
bioactivity consisted of adding COOH on the R position (similar to R1 on Spipethiane
earlier) to yield a pKi of 1.5842 vs 1.2858 (literature pKi as 1.0969); this could potentially
mean a Ki value of 0.03 nM (literature value is 0.08 nM).
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Table 3.14:

PD144418-based Ligands

Compounds

R

Lit. pKi

HF/6-31G*

B3LYP/6-31G*
Predicted pKi

41

H

1.0969

1.096

1.2858

54

Cl

N/A

1.0975

1.425

N/A

0.5144

1.1845

N/A

0.1275

0.2823

N/A

1.0129

1.5842

N/A

1.4306

1.4538

55

56
(diamantane)

57
58

F
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Table 3.15: Additional PD144418-based Ligands (Comparison With Second R Group)

Compounds

R1

R2

HF/6-31G*

B3LYP/6-31G*
Predicted pKi

59
60

H

tbutyl

0.6897

1.0166

tbutyl

1.0846

1.2685

Figures 3.60 and 3.61 demonstrate a situation where the molecule minimized in a way
that the Cl added as the R group could not reach the red area of electronegativity
desirable as well as expected, however the bioactivity did improve, minimally for HF/631G*. B3LYP/6-31G* had slightly better improvement yielding a bioactivity of 1.425
vs 1.2858.
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Figure 3.60 Contour map of compound 54 at HF/6-31G*.

Figure 3.61 Contour map of compound 54 at B3LYP/6-31G*.
Figures 3.62 and 3.63 demonstrate a situation where the molecule minimized in a way
that the cyclohexyl with CO added as the R group overlapped to the yellow undesirable
area. Also the O atom did not overlap into the desirable red electronegative area.
Therefore, the bioactivity did not improve for compound 55.
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Figure 3.62 Contour map of compound 55 at HF/6-31G*.

Figure 3.63 Contour map of compound 55 at B3LYP/6-31G*.
In an attempt to overlap the bulk desirable areas of the contour maps in Figures 3.64 and
3.65, diamantane was added as the R group for compound 56. The bioactivity did not
improve, however, even though part of diamantane overlapped the green areas.

81

Figure 3.64 Contour map of compound 56 at HF/6-31G*.

Figure 3.65 Contour map of compound 56 at B3LYP/6-31G*.
COOH was added as the R group for Figures 3.66 and 3.67 in compound 57. Though the
minimization of the molecule appears to present another case where the R group could
not overlap well with the red desirable electronegative areas, the bioactivity improved for
the B3LYP/6-31G* CoMFA model, yielding the aforementioned 1.5842 value.
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Figure 3.66 Contour map of compound 57 at HF/6-31G*.

Figure 3.67 Contour map of compound 57 at B3LYP/6-31G*.
F was added as the R group for Figures 3.68 and 3.69 in compound 58. In this case the F
consistently overlapped the red electronegative areas and improved the bioactivity on
both HF/6-31G* and B3LYP/6-31G* levels at 1.4306 and 1.4538, respectively (vs 1.096
and 1.2858).
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Figure 3.68 Contour map of compound 58 at HF/6-31G*.

Figure 3.69 Contour map of compound 58 at B3LYP/6-31G*.
There was an additional combination considered based on the successful results from the
newly designed ligands based on Spipethiane. Therefore, for Table 3.15, R2 used a
tertiary butyl group and the consideration of H or COOH was used for R1. The results
show that there is no improvement in bioactivity even though the tbutyl group overlaps
well with the green desirable bulk area in Figures 3.70 – 3.73. Further, due to the
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minimization of the molecule, the added COOH did not overlap with the red
electronegative desirable area.

Figure 3.70 Contour map of compound 59 at HF/6-31G*.

Figure 3.71 Contour map of compound 59 at B3LYP/6-31G*.
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Figure 3.72 Contour map of compound 60 at HF/6-31G*.

Figure 3.73 Contour map of compound 60 at B3LYP/6-31G*.

Note that there were attempts to add diamantane as an R1 group to explore adding bulk
further to compound 43, spipethiane (as it was done for PD144418), however the
resulting molecules did not minimize successfully and were therefore aborted. Similarly,
adding a cyclohexane ring attached to a C=O group at the R1 location also did not
minimize successfully for Spipethiane; this particular combination was aimed at
exploring bulk combined with electronegativity.
Therefore, for both compound 41, PD144418, and compound 43,Spipethiane, the
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best cases of completed optimizations at both calculation levels with increases in activity
were due to the addition of electronegative substituents or groups such as fluorine,
chlorine and COOH. It was also observed that adding the tbutyl group in the R2 position,
while having an electronegative group such as COOH at R1, for Spipethiane increased
the activity. Certainly these are promising results, leading to the possibility that the newly
predicted highly active ligands could be synthesized and potentially used in the future as
drug candidates.
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CHAPTER 4
MOLECULAR MODELING OF SIGMA 2 RECEPTOR LIGANDS

4.1 Introduction
It is generally acknowledged that there is less knowledge about the sigma 2 receptor as
opposed to the sigma 1 receptor due to the lack of high-affinity, selective ligands (Berardi
et al., 2004). The sigma 2 receptor has not been cloned as the sigma 1 receptor has (Abate
et al., 2011). Lack of knowledge surrounding sigma 2 receptors, however, does not bear
any relationship to the importance of the sigma 2 receptors. In fact, sigma 2 receptor
ligands have been studied for treatment of pancreatic cancer because they are
preferentially internalized by proliferating cells and induce apoptosis; multiple sigma 2
receptor ligands, even up to 10 nM affinity, are shown to decrease tumor burden in
preclinical models of human pancreatic cancer (Hornick et al., 2012). Interest in sigma 2
receptors has been increasing especially since sigma 2 receptors are overexpressed in a
wide variety of human tumor cell lines, representing biomarkers for the diagnosis of
tumors with non-invasive techniques such as Positron Emission Tomography (PET ) or
Single Photon Emission Computed Tomography (SPECT) (Abate et al., 2011).
Therefore, finding high-affinity, selective sigma 2 ligands is on the rise, however known
sigma 2 receptor ligands generally exhibit a poor selectivity profile, particularly over the
sigma 1 receptor (Berardi et al., 2003). Many of the researchers in the literature have
synthesized and studied sigma 2 receptor ligands; comparatively, the affinity values to
the sigma 1 receptor ligands are much higher. There is a focus on increased selectivity,
however. Even if the affinity values do not appear as strong as what is displayed for
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sigma 1 ligands, there seems to be increased emphasis on the concept of selectivity to
ensure there is not competition from sigma 1 ligands in the radioligand studies (Berardi et
al., 2004; Fan et al., 2011; Hajilour et al., 2011;).
Though the Gund group has done some pharmacophore and CoMFA studies on sigma
2 receptor ligands through theses, published models in scholarly journals do not exist as
they do for the sigma 1 receptor ligands at this time. Some comparison to the theses’
models exist in Section 4.4.1 as well as to a representative external model.

4.2 Selection of Ligands
Overall sigma 2 receptor ligands in the present study were selected based on compounds
that were shown to be active for sigma 2 while also being selective for sigma 2. Naturally
all of the studies used radioligand competitive binding assays with [3H]-DTG along with
(+)-pentazocine to block sigma binding sites (Berardi et al., 2004; Fan et al.,
2011Hajilour et al., 2011;).
Compounds 1-18 for sigma 2 receptor ligands were selected especially due to the fact
that PB28, a sigma 2 receptor ligand with very high affinity (0.34 nM, compound 5), is a
member of this class; therefore it is quite fitting to study derivatives of 1Cyclohexylpiperazine to determine if those compounds will yield similar binding
affinities or selectivities (Berardi et al., 2004). Additionally, Wirpsza and Patel had used
several of these molecules in their modeling studies as part of the earlier work on sigma 2
receptor ligands with the Gund group (Wirpsza, 2008; Patel, 2010) The series studied in
the current work are displayed in Table 4.1.
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Table 4.1 Binding and Functional Data of 4-(Tetralin-1-yl) and 4-(Naphthalen-1-yl)alkyl
Derivatives of 1-Cyclohexylpiperazine

Compound

R

R1

n

σ1Ki(nM)

σ2Ki(nM)

σ1/ σ2

1

A

5-OCH3

0

0.40 ± 0.02

7.90 ± 1.60

20

2

A

5-OCH3

1

0.31 ± 0.10

16.4 ± 4.2

53

3

A

5-OCH3

2

1.57 ± 0.41

21.1 ± 3.4

13

4

A

H

3

0.61 ± 0.08

0.68 ± 0.03

1.1

5*

A

5-OCH3

3

13.6 ± 1.9

0.34 ± 0.02

6

A

6-OCH3

3

0.36 ± 0.12

5.42 ± 0.64

7

A

7-OCH3

3

9.04 ± 1.02

1.22 ± 0.17

8

A

H

4

0.036 ± 0.015

14.6 ± 3.7

406

9

A

5-OCH3

4

1.54 ± 0.36

3.58 ± 0.55

2.3

10

A

H

5

1.45 ± 0.35

7.85 ± 0.49

5.4

11

A

5-OCH3

5

1.52 ± 0.63

0.35 ± 0.09

12

A

5-OCH3

6

3.07 ± 0.70

103 ± 23

13

A

5-OH

3

5.40 ± 0.40

2.66 ± 0.66

14

A

6-OH

3

0.69 ± 0.05

1.12 ± 0.17

15

B

H

3

2.16 ± 0.63

0.69 ± 0.08

16

B

OCH3

3

1.57 ± 0.15

9.24 ± 1.37

5.9

17

B

H

4

0.22 ± 0.03

30.5 ± 8.7

139

18

B

H

5

2.40 ± 0.47

0.57 ± 0.08

40
15
7.4

4.3
34
2
1.6
3.1

4.2

*Indicates included in the comprehensive sigma 2 pharmacophore derivation.
Source: Berardi et al., 2004.
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σ2/ σ1

5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,3dimethoxy-benzamide (compound 19) is one of the most potent and selective sigma 2
receptor ligands reported with 8.2 nM affinity accompanied by 1573-fold selectivity over
sigma 1 sites (Fan et al., 2011). Therefore, it is important to conduct molecular modeling
on this molecule, compound 19, along with a series of new analogs where the amine ring
fused to the aromatic ring was varied in size (Fan et al., 2011). These molecules,
compounds 19 – 28, are located in Table 4.2.

Table 4.2 Binding and Functional Data of Substituted Aminobutyl-benzamides

19

20

22

21

23

Source: Fan et al., 2011.
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24

Table 4.2 (continued) Binding and Functional Data of Substituted Aminobutylbenzamides

25

26

27

28
Compound

σ1Ki(nM)

σ2Ki(nM)

σ1/ σ2

19*

12,900

8.2

1573

20

881 ± 15

2.7 ± 0.1

326

21

880 ± 60

4616 ± 247

0.2

22

1442 ± 88

0.82 ± 0.06

1758

23

5073 ± 82

734 ± 50

8.5

24

4521 ± 45

9681 ± 522

0.47

25

2068 ± 60

315 ± 15

6.58

26

2564 ± 175

8957 ± 335

0.29

27

4499 ± 182

5823 ± 224

0.77

28

583 ± 28

2126 ± 240

0.27

*Indicates included in the comprehensive sigma 2 pharmacophore derivation.
Source: Fan et al., 2011.
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Compounds 29-37 represent molecules where the contribution of electrondonating and electron-withdrawing groups were explored through synthesis and
characterization of new compounds featuring a benzamide moiety and an isoquinoline
moiety linked by an alkyl chain (Hajipour et al., 2011). Hajipour and coworkers focused
on the concept of improving selectivity for the sigma 2 receptor (2011). These molecules
are in Table 4.3.

Table 4.3 Binding and Functional Data of Benzamide-isoquinoline Derivatives

29

30

32

35

33

36

31

34

37

Source: Hajipour et al., 2011.
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Table 4.3 (continued) Binding and Functional Data of Benzamide-isoquinoline
Derivatives

Compound

σ2Ki(nM)

σ1Ki(nM)

σ1/ σ2

29

26.78 ± 2.92

10,320 ± 363

385

30

12,930 ± 55.77

7,870 ± 264

0.61

31

866.70 ± 138.6

74,680 ± 305

86.17

32

4,000 ± 177.9

11,200 ± 469

2.80

33

1,400 ± 286

67,800 ± 4.155

48.40

34

5,290 ± 408

>107

35

152,000 ± 4,106

14,690± 1,121

0.096

36

>107

1.21 × 106

0.29

37*

21.26 ± 2.41

87.5 ± 3.07

4.12

*Indicates included in the comprehensive sigma 2 pharmacophore derivation.
Source: Hajipour et al., 2011.

Some of the work in the 1990s included comparison of binding parameters for
sigma 1 and sigma 2 in rat and guinea pig brain membranes using a trishomocubane
series by Nguyen and colleagues (Nguyen et al., 1996). Some molecules from this series
were included in this work so that an additional sigma 2 class could be included,
especially since the series was studied by Jung during the earlier work on sigma 2 for the
Gund group (Jung, 2004). Also, reference compound 57 discussed later in this section is a
trishomocubane derivative compound which is another reason why it is fitting to include
several other molecules from the series. Table 4.4 summarizes the subset of
trishomocubanes used in the current study for pharmacophore and CoMFA model
development.
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Table 4.4: Trishomocubane Subset of Compounds

n=1
Compound

X

Y

σ2Ki(nM)

σ1Ki(nM)

σ1/ σ2

38

OCH3

H

136 ± 19

103 ± 1

0.76

39

H

Cl

30 ± 1

186 ± 8

6.2

40

H

Br

40 ± 22

208 ± 13

5.20

41

H

I

54 ± 18

169 ± 10

3.13

42

H

CH3

108 ± 6

97 ± 6

0.90

Source: Nguyen et al., 1996.

In previous work by the Gund group, a large series of 1-aralkyl-4—
benzylpiperazine derivatives was studied by both Wirpsza and Patel based on Costantino
and coworkers’ research (Costantino, 2004; Wirpsza, 2008; Patel, 2010). A subset of
seven molecules, presented in Table 4.5, were chosen to include from the previous Gund
work in order to build on the foundation of the sigma 2 studies, expanding the sigma 2
class type for the pharmacophore representative model as well as the CoMFA models for
this work.
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Table 4.5 : 1-aralkyl-4-benzylpiperazine Derivatives Subset

σ2Ki(nM)

σ1Ki(nM)

σ1/ σ2

43

1.70

0.80

0.47

44

1.48

0.30

0.20

45*

1.59

0.30

0.19

46

3.02

0.30

0.10

47

25.6

15.4

0.60

48

4.75

1.20

0.25

49

5.35

2.66

0.50

Compound

R

Sources: Costantino et al., 2005 and Patel, 2010.
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Several reference molecules were included in the pharmacophore derivation for
the sigma 1 representative pharmacophore and CoMFA studies as explained in Chapter 3.
Similarly, three rigid references were added to the dataset for the sigma 2 ligand models.
The references previously used by the Gund group for sigma 2, also used in the current
study, are shown in Table 4.6. Also note that Haloperidol, compound 53, was included as
an additional flexible molecule as a means to later (in Chapter 5) compare the differences
between sigma 1 and sigma 2 since it is active for both; it was included in the sigma 1 set
in Chapter 3. Therefore, Haloperidol was used in the test set for both sigma 1 and sigma 2
and was not used as a molecule in the construction of the CoMFA model. This is a key
point because the activity data varied for this molecule in various studies by researchers.
The data included in Table 4.6 for Haloperidol is not from Gund (2003) as in the sigma 1
analysis for Chapter 3; instead more recent data was used for sigma 2 ligand studies by
Fan et al., especially because the aminobutyl-benzamide series, studied in this work and
included in the models, came from the same study (2011). The activity data served as a
means to compare the test set data primarily for each CoMFA model.
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Table 4.6: Binding and Functional Data of Reference and Other Compounds

50 1,3-di (2-tolyl) guanidine (DTG)

51

BIMU-1

52 ANSTO-19 (Trishomocubane Derivative)

53

Haloperidol

Compound

σ2Ki(nM)

σ1Ki(nM)

σ1/ σ2

50*

13.4 ± 2.0

7436 ± 308

554.93 (Berardi et al., 2004)

51*

32 ± 15.2

6300

52*

20 ± 4

53

9.58 ± 0.98

-

(Bonhaus et al., 1993)

152 ± 1

7.60

(Nguyen et al., 1996)

0.83 ± 0.03

11.5

(Fan et al., 2011)

*Indicates included in the comprehensive sigma 2 pharmacophore derivation.
Sources: Wirpsza, 2010 (original data sources listed above as specified by Wirpsza for compounds 55-57).
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4.3 Materials and Methods
All molecules were initially drawn in Spartan ’14 and then optimized at the HF/6-31G*
and B3LYP/6-31G* levels prior to being imported into the SYBYL-X 2.1 program.
Molecular databases were created within SYBYL-X 2.1 to represent each class of
compounds for the sigma 2 receptor ligands. DISCOtech, a tool within SYBYL-X 2.1,
was then used to generate pharmacophores for each of the classes. Pharmacophore
development for each set of selected molecules was conducted by utilizing the options
within DISCOtech for feature selection (binding site), conformer searches, etc. to yield
potential pharmacophore models. Following the development of pharmacophore models
for each class, a database was created to include the most active/lead compounds with
some rigid references and active references from the previous work by Gund and
colleagues. This database was then utilized to develop a comprehensive pharmacophore
to represent all of the sigma 2 ligand classes studied in this work. Once pharmacophore
models were completed, the Comparative Molecular Field Analysis models were created
for the sigma 2 molecules calculated at HF/6-31G* and B3LYP/6-31G* levels,
respectively. Note that that the approach described in Chapter 3 for the sigma 1 ligands
utilized in the CoMFA models was slightly different for sigma 2 ligands since the
bioactivities varied so much; therefore the most active compounds from each of the
classes were selected to yield a training set range between 3 and 4 log units (similar to the
range for sigma 1 ligands in Chapter 3) since some of the activities for the molecules for
sigma 2 were extremely poor. New ligands were designed once the CoMFA models were
determined to meet robust criteria; contour maps generated from the CoMFA models
were studied during the new ligand design process. Additional information about the
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pharmacophore derivation, CoMFA and design of new ligands are in Sections 4.4, 4.5,
and 4.6, respectively.
4.4 Pharmacophore Derivation
DISCOtech allows the researcher to manually select the binding features of each
molecule to be considered for pharmacophore generation. For these classes, hydrophobic
groups, positive nitrogen and lone pair were used. This was done via an iterative process.
First, models were explored without constraints or features selected, and gradually
various combinations of binding groups were included. Specifics regarding each class
and the derivations are discussed in Section 4.4.1.

4.4.1

Pharmacophore Models

Pharmacophores were generated using DISCOtech in SYBYL-X 2.1 for each class of
compounds and are shown as labelled in Figures 4.1 through 4.15. Similar to sigma 1, the
main binding sites are the nitrogen site, the lone pair of electrons and a hydrophobic
group, however an additional hydrophobic group was also used as a binding site on the
opposite side of the N atom, producing a modified “pyramid” type pharmacophore with
the exception of one class; the substituted benzamide-isoquinolines had a “triangle” type
pharmacophore, however with different distances than observed in the sigma 1 work. The
comprehensive pharmacophore to represent all of the sigma 2 classes studied in this work
are in Figures 3.16 through 4.18. The distances for the 4-point pharmacophore are noted
in the figures with more discussion around the comprehensive pharmacophore.
Figures 4.1 – 4.3 depict the pharmacophore development for the 18 molecules of
the 1-cyclohexylpiperazine series. The length of the molecules in this series varied
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greatly and therefore the hydrophobic point for the phenyl groups, on the side with the
additional CH2 groups in-between, is seen among the chains/phenyl rings on the side of
the phenyl rings.

Figure 4.1 DISCOtech pharmacophore derivation of 1-cyclohexylpiperazines
(compounds 1-18, hydrogen atoms hidden). Purple sphere = lone pair, red sphere = N
atom and green spheres = hydrophobic points.
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Figure 4.2 DISCOtech pharmacophore derivation of 1-cyclohexylpiperazines
(compounds 1-18), overlay with compound 5, PB 28 (hydrogen atoms hidden). Purple
sphere = lone pair, red sphere = N atom and green spheres = hydrophobic points.

Figure 4.3 DISCOtech pharmacophore derivation of 1-cyclohexylpiperazines
(compounds 1-18). Purple sphere = lone pair, red sphere = N atom and green spheres =
hydrophobic points.
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The aminobutyl-benzamide pharmacophore development is shown in Figures 4.4 - 4.6.
These molecules have a similar pharmacophore to the previous class with the 1cyclohexylpiperazines, however the lengths between the binding groups (hydrophobic/N
atoms) are generally longer due to the fact that the molecules are a long series. The 6
molecules with highest bioactivity values were used for this series, as some of the activity
values were extremely poor.

Figure 4.4 DISCOtech pharmacophore derivation of substituted aminobutyl-benzamides
(compounds 19, 20, 22, 23, 25, and 28, hydrogen atoms hidden). Purple sphere = lone
pair, red sphere = N atom and green spheres = hydrophobic points.

Figure 4.5 DISCOtech pharmacophore derivation of substituted aminobutyl-benzamides,
overlay with compound 20 – hydrogen atoms hidden . Purple sphere = lone pair, red
sphere = N atom and green spheres = hydrophobic points.
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Figure 4.6 DISCOtech pharmacophore derivation of substituted aminobutyl-benzamides
(compounds 19-28). Purple sphere = lone pair, red sphere = N atom and green spheres =
hydrophobic points.
Figures 4.7 – 4.9 depict the pharmacophore development for the benzamide-isoquinoline
series. The series consisted of mostly poor activities, with the exception of

two

molecules with high bioactivity, which may account for the difficulty in modeling the
pharmacophore. It was found that a three point pharmacophore was more appropriate for
this class specifically; the hydrophobic area on the other side of nitrogen, when chosen as
a binding feature, was difficult to include in the program.

104

Figure 4.7 DISCOtech pharmacophore derivation of substituted benzamide-isoquinoline
derivatives (compounds 29-37, hydrogen atoms hidden). Purple sphere = lone pair, red
sphere = N atom and blue-green sphere = hydrophobic point.

Figure 4.8 DISCOtech pharmacophore derivation of substituted benzamide-isoquinoline
derivatives (compounds 29-37), overlay with compound 37 - hydrogen atoms hidden.
Purple sphere = lone pair, red sphere = N atom and blue-green sphere = hydrophobic
point.
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Figure 4.9 DISCOtech pharmacophore derivation of substituted benzamide-isoquinoline
Derivatives (compounds 29-37). Purple sphere = lone pair, red sphere = N atom and bluegreen sphere = hydrophobic point.

Figures 4.10 - 4.12 present another pyramid-type pharmacophore, in this case for the
trishomocubane series, however the distances between the N and hydrophobic groups is
much smaller as compared to the previous sigma classes studied thus far.

Figure 4.10 DISCOtech pharmacophore derivation of substituted trishmocubane subset
(compounds 38-42, hydrogen atoms hidden). Purple sphere = lone pair, red sphere = N
atom and blue/green spheres = hydrophobic points.
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Figure 4.11 DISCOtech pharmacophore derivation of substituted trishmocubane subset
(compounds 38-42), overlay with reference molecule compound 52 (hydrogen atoms
hidden). Purple sphere = lone pair, red sphere = N atom and blue/green spheres =
hydrophobic points.

Figure 4.12 DISCOtech pharmacophore derivation of substituted trishmocubane subset
(compounds 38-42). Purple sphere = lone pair, red sphere = N atom and blue/green
spheres = hydrophobic points.
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Figures 4.13 through 4.15 present the pharmacophore model for 1-aralkyl-4benzylpiperazine derivatives studied in this work. Similarly, it presents a 4-point
pharmacophore, however, the distances between the N atom and hydrophobic groups are
a little less than the earlier classes (with the exception of the trishomocubanes), though
there is the question of the hydrophobic area being the area before the phenyl or whether
it is the phenyl ring (which would mean a slightly longer distance). The model developed
here was the “cleanest” version with very good overlap for the conformers generated by
DISCOtech. Note that it is slightly different in molecule conformation (overall) vs the
previous molecules; though the pharmacophore is a pyramid-type, the piperazine is not as
“straight” as noted for the other cyclohexyl-type rings in previous molecules. In fact, the
way the piperazine piece lines up is similar to the close alignment of the N atoms
observed in the sigma 1 pharmacophore development and CoMFA studies, which may
explain why this class also shows high activity for sigma 1. Some of the other classes in
this study for sigma 2 are more selective for sigma 2 than sigma 1.

Figure 4.13 DISCOtech pharmacophore derivation of 1-aralkyl-4-benzylpiperazine
derivatives subset (compounds 43-49, hydrogen atoms hidden). Purple sphere = lone pair,
red sphere = N atom and blue/green spheres = hydrophobic points.
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Figure 4.14 DISCOtech pharmacophore derivation of 1-aralkyl-4-benzylpiperazine
derivatives subset (compounds 43-49), overlay with compound 43 - hydrogen atoms
hidden. Purple sphere = lone pair, red sphere = N atom and blue/green spheres =
hydrophobic points.

Figure 4.15 DISCOtech pharmacophore derivation of 1-aralkyl-4-benzylpiperazine
derivatives subset (compounds 43-49). Purple sphere = lone pair, red sphere = N atom
and blue/green spheres = hydrophobic points.
Figures 4.16 – 4.18 represent the comprehensive pharmacophore development for sigma
2, where lead compounds were selected from each class along with some rigid references
to yield a representative pharmacophore for the sigma 2 subtype; the compounds chosen
were compounds 5, 19, 37, 45, 50, 51 and 52. Compound 5, PB 28 – the most active
sigma 2 ligand – was used as the reference in the pharmacophore generation in
DISCOtech. Note that the distance between the lone pair and the N atom is 2.9 Å,

109

whereas the distance between the N atom and one hydrophobic point is 2.9 Å and the
other distance is 5.47 Å. The other part of the triangle piece, on the opposite side of 5.47
Å length is 6.37 Å, the distance between the lone pair and the hydrophobic point, whereas
the distance between the lone pair and the phenyl group on the right side of the figures is
4.8 Å. The distance between the two hydrophobic groups is 8.17 Å. As discussed during
the

1-aralkyl-4-benzylpiperazine

model

explanation,

generally

the

sigma

2

pharmacophore does not depict close or directional overlay of the N from the
cyclohexyl/piperazine piece of the molecules; in general there is a pharmacophoric point
there, but it is also weighted by the two (instead of one) pharmacophoric hydrophobic
points on either side or it. This is a key point because this pharmacophore shape was
applied to the CoMFA studies for sigma 2 with successful results, as the models were
considered robust by the criteria in Section 2.2.2. Therefore, it seems that the main
difference between the sigma 1 and sigma 2 pharmacophores is the matter of 3-points vs
4 points due to the additional hydrophobic group. This was observed visually in the
sigma 2 CoMFA alignments in Figures 4.23 and Figures 4.24 where the hydrophobic
groups are more clearly clustered on both sides of the N as opposed to only the one
hydrophobic cluster, the thiophene/phenyl overlay seen in the sigma 1 CoMFA
alignments.
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Figure 4.16 Comprehensive DISCOtech pharmacophore derivation for Sigma 2
(compounds 5, 19, 37, 45, 50, 51 and 52 – hydrogen atoms hidden). Purple sphere =
acceptor site, red sphere = positive nitrogen and blue-green spheres = hydrophobic
centers.

Figure 4.17 Comprehensive DISCOtech pharmacophore derivation for Sigma 2, overlay
with compound 5 (hydrogen atoms hidden). Purple sphere = acceptor site, red sphere =
positive nitrogen and blue-green spheres = hydrophobic centers.
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Figure 4.18 Comprehensive DISCOtech pharmacophore derivation for Sigma 2. Purple
sphere = acceptor site, red sphere = positive nitrogen and blue-green spheres =
hydrophobic centers.

The current comprehensive pharmacophore model for sigma 2 in Figures 4.16 through
4.18 was compared with previous sigma 2 pharmacophores from the Gund group. Patel
had a three-point pharmacophore, which encompasses part of the current pharmacophore,
with the N atom and hydrophobic group (2010). Figure 4.19 highlights some similarities
in the distances between the models.
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(a)

(b)
Figure 4.19 Comparison of Comprehensive DISCOtech pharmacophore (a) from Figure
4.17 with pharmacophore derived by Patel (b).

Source: (b) Patel, 2010

The current comprehensive pharmacophore model for sigma 2 in Figures 4.16 through
4.18 was compared to Jung’s model. Jung had a three-point pharmacophore, which
encompasses part of the current pharmacophore, with the N atom and hydrophobic group
(2003). Figures 4.20 highlights the similarities in the distances between the models.
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(a)

(b)
Figure 4.20 Comparison of Comprehensive DISCOtech pharmacophore (a) from Figure
4.17 with pharmacophore derived by Jung (b).
Source: (b) Jung, 2003

The current comprehensive pharmacophore model for sigma 2 in Figures 4.16 through
4.18 was compared to Wirpsza’s model . Wirpsza had a four point pharmacophore,
similar to the current pharmacophore (2008). Note that nearly all the distances are very
close with the exception of the distance between the hydrophobic groups. This can be
explained by the fact that compound 5, PB 28, was used as the reference for the current
work since it was deemed to be the most active compound for sigma 2, whereas Wirpsza
used the default reference in DISCOtech which could mean a smaller distance between
the hydrophobic groups if that molecule was not as active. Figure 4.21 highlights the
similarities in the distances between the models.
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(a)
(b)

Figure 4.21 Comparison of Comprehensive DISCOtech pharmacophore (a) from Figure
4.17 with pharmacophore derived by Wirpsza (b).
Source: (b) Wirpsza, 2008

This study aimed to resolve the model differences from the past by the Gund group and
was able to do so successfully; the current pharmacophore in Figures 4.16 – 4.18 could
be considered a “hybrid” model which includes aspects of all of the other models,
including all of the classes the other researchers studied while using the most active
reference for DISCOtech to yield a more representative, active pharmacophore model.
This model was compared with those seen in the literature. Rhoades and colleagues
recently published a paper about a comprehensive sigma 2 pharmacophore (2014). They
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note that the other models they compared with from other researchers were very
molecule/class-specific (Rhoades et al., 2014). Therefore, the researcher for this study
compared with Rhoades’ model who aimed to develop a representative sigma 2
pharmacophore (2014). The work done by Rhoades and colleagues was very extensive,
with approximately 100 pharmacophore models which they ranked, clustered and
analyzed (Rhoades et al., 2014). Figure 4.22 is the best model for comparison for our
case, as “Group 2” as explained, was the best ranked as it had ties to analysis yielding
high q2 values, however the application of the robust criteria was not explicitly observed
in the paper (it is unclear if it had been performed as there is no mention to Golbraikh and
colleagues, however other statistical values were calculated and discussed) (Rhoades et
al., 2014). Nevertheless, Figure 4.22 depicts two pharmacophores by Rhoades and
colleagues with some similarity around P1 (positive nitrogen), however the hydrophobic
point locations are different and they have chosen donor sites, not an acceptor site
associated with the N atom as chosen in this study. The approach Rhoades and colleagues
took was different than the one taken here where they do not have a very active molecule
such as PB 28 in the study. Further, the energy/calculation levels associated with the
QSAR/electrostatics taken by Rhoades is not clear. Each researcher has a different
approach and therefore there are variations in the models. From the current work, the
leading pharmacophore in Figure 4.16 – 4.18 is postulated, especially since it was applied
during the CoMFA model alignment quite successfully.
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Figure 4.22 Pharmacophore models by Rhoades and colleagues. R1 = aromatic, H1/H2 =
hydrophobic, D1/D2 = donor sites and P1 = positively charged site.
Source: Rhoades et al., 2014.

4.5 Comparative Molecular Field Analysis
4.5.1 Geometry Optimization and Electrostatic Studies
Each molecule in this study was optimized and saved at the ab initio HF/6-31G* and
density functional B3LYP/6-31G* levels with electrostatic charges corresponding to each
calculation level. Once each molecule was optimized, it was saved as a “.mol2” file with
“electrostatic” to carry the corresponding geometry and calculated electrostatic charges
into SYBYL-X 2.1.

117

4.5.2 Alignment
Alignment of the HF/6-31G* and B3LYP/6-31G* optimized geometries for the sigma 2
ligands was an essential step in generating a CoMFA model for each calculation level,
respectively. A key point is that this was a rigid alignment approach with the intent to
maintain the bound conformation of each molecule at the calculation level being studied.
Many researchers, however, use flexible alignment approaches; as an example, Caballero
and researchers state that their 3D-QSAR models rely on the arbitrary alignment of
conformationally flexible ligands (2012). Since part of the objective of this study was to
observe the results, comparing ab initio with density functional methods, and also since
the conformation is unknown for each molecule when it binds to the sigma 2 receptor, the
assumption was made that the energy should be minimized. Therefore the ab initio and
density functional methods calculated energy minimized geometries while also
calculating the electrostatic charges. The resulting molecules were then rigidly aligned to
each other.
The approach to alignment for the sigma 2 ligands consisted of first applying the
DISTILL RIGID tool for the 1-aralkyl-4-benzylpiperazine molecules since those
conformations were very close visually and therefore very tight alignment could be
initiated for the sigma 2 ligands with that class. Then compound 5 (PB 28), considered
the template molecule overall for the CoMFA alignment especially since it was the
reference compound in the comprehensive pharmacophore model, was aligned with the
already aligned 1-aralkyl-4-benzylpiperazine class. Then DISTILL RIGID was applied to
the 1-cyclohexylpiperazines. The lead compound from the benzamide-isoquinoline
derivatives was aligned to compound 5, with the remaining molecules then aligned to the
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lead via ALIGN DATABASE. The same approach was taken for the aminobutylbenzamides. Trishmocubanes were aligned via the nitrogen atom to compound 5.
References were similarly aligned via the “match atoms” function using the N and
surrounding carbon atoms. Then the benzamide-isoquinoline derivatives were further
aligned via the “match atoms function” choosing the phenyl ring and N and surrounding
carbon atoms. The q2 for HF/6-31G* and B3LYP/6-31G* were 0.528 and 0.544,
respectively.
Consistent with the robust criteria described in Section 2.2, 5 molecules were
chosen as the test set with the remaining 26 molecules acting as the training set.
Additional details are provided in Section 4.5.3. The final alignment of all 31 molecules
can be viewed in Figure 4.23 for HF/6-31G* and Figure 3.24 for B3LYP/6-31G*. The
resulting alignments led to robust models as described in Section 2.2.2. Additional details
about the CoMFA models are described in Section 4.5.3.
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Figure 4.23

Alignment of all 31 sigma 2 ligands at the HF/6-31G* calculation level.

Figure 4.24
level.

Alignment of all 31 sigma 2 ligands at the B3LYP/6-31G* calculation
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4.5.3 Quantitative Structure Activity Data Analysis
The CoMFA models were initiated by first conducting the molecular alignment as
described in Section 4.5.2. Each activity (Ki) value was converted to a pKi value using
Equation 2.4. The training set for the CoMFA ensured a range of at least 3 log units in
terms of pKi, as is suggested in the field and demonstrated by other researchers (Bolden
et al., 2013). The training set ranged from -3.1462 to 0.4685 whereas the test set ranged
from -2.9379 to -0.48 log units. The histograms of the pKi vs number of molecules are
shown in Figures 4.25A and 4.25B.

Figure 4.25A Histogram of frequency vs pKi for sigma 2 ligands in training set.
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Figure 4.25B Histogram of frequency vs pKi for sigma 2 ligands in test set.
The CoMFA models were constructed using the default settings in SYBYL-X 2.1.
Therefore, an sp3 hybridized carbon atom was probed with a +1.0 unit charge which
extended at least 4 Å beyond each molecule, 2.0 Å grid spacing and the default 30
kcal/mol energy cutoff for steric and electrostatic fields. The CoMFA column, combined
with the literature pKi values, generated the Partial Least Squares cross-validated q2 for
each set, resulting in a predicted bioactivity (pKi) value for each training set molecule.
The test set, molecules which were not used to create the model, was used to validate the
model by comparing predicted bioactivities generated with the experimental results. The
resulting sigma 1 dataset at HF/6-31G* with 36 molecules in the training set resulted in a
q2 value of 0.528; the predicted bioactivity values for that set is in Table 4.7. The
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resulting sigma 1 dataset at B3LYP/6-31G* with 26 molecules in the training set resulted
in a q2 value of 0.544; the predicted bioactivity values for that set is in Table 4.7. Table
4.8 shows the results for the test set.
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Table 4.7:
Experimental and Predicted Bioactivities (pKi) by the Training Set of
Sigma 2 Compounds using ab initio and Density Functional Calculation Methods
Compounds

Lit. pKi

HF/6-31G*

B3LYP/6-31G*
Predicted pKi

5

0.4685

0.0313

0.5584

6

-0.734

-0.6151

-0.7734

7

-0.0864

-0.4827

-0.1277

13

-0.4249

-0.0658

-0.4706

14

-0.0492

-0.0078

-0.0809

19

-0.9138

-0.7067

-0.9242

20

-0.4314

-0.6527

-0.4761

22

0.0862

-0.1115

0.0781

23

-2.8657

-2.9031

-2.8122

25

-2.4983

-2.698

-2.5214

29

-1.4278

-1.6768

-1.423

33

-3.1461

-3.1

-3.1764

37

-1.3276

-1.307

-1.3004

38

-2.1335

-1.9038

-2.2583

40

-1.6021

-1.6407

-1.5547

41

-1.7324

-1.6586

-1.6701

42

-2.0334

-1.7699

-1.9121

43

-0.2304

-0.3102

-0.1726

44

-0.1703

-0.3759

-0.2927

45

-0.2014

-0.2972

-0.1155

47

-1.4082

-0.5968

-1.3412

48

-0.6767

-0.5132

-0.7251

49

-0.7284

-0.6895

-0.7325

50

-1.4502

-1.5098

-1.4138

51

-1.5051

-1.2912

-1.4476

52

-1.301

-1.6708

-1.4377
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Table 4.8:
Experimental and Predicted Bioactivities (pKi) by the Test Set of Five
Sigma 2 Compounds using ab initio and Density Functional Calculation Methods
Compounds

Lit. pKi

HF/6-31G*

B3LYP/6-31G*
Predicted pKi

4

0.1675

-0.1008

0.0541

31

-2.9379

-2.1729

-2.0907

39

-1.4771

-1.6445

-1.5026

46

-0.48

-0.5441

-1.0786

53

-0.9814

-1.3519

-1.2244

The Partial Least Squares Analysis (PLS), as described in Section 2.2.1, was used
by applying the SAMPLS algorithm in SYBYL-X 2.1 developed by Bruce Bush. The
optimum number of components was determined by the SYBYL-X 2.1 in the output
report from the SAMPLS algorithm and is shown in bold in Table 4.8. For the HF/631G* calculation level, the QSAR module used 2 components for the model, however
SAMPLS, during the PLS application, stated 4 components was the optimum. In this case
the originally chosen 2 component model was used, especially since the q2 value
decreased at the next component addition as observed in Table 4.9. The number of
optimal components identified in Table 4.8 was then applied without cross-validation
yielding the results in Table 4.10. The R2 values for HF/6-31G* and B3LYP/6-31G*
without cross-validation, using the optimal number of components for each, respectively,
at 5 and 4 yielded 0.920 and 0.995. Note that Table 4.10 also presents the electrostatic
and steric contributions to the CoMFA field.
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Table 4.9: Optimal Component Number and q2 by “Leave-One-Out” using SAMPLS by
the Training Set of 26 Molecules

Lev.

Term

C. 1

C. 2

C. 3

C. 4

C. 5

C. 6

C. 7

C. 8

C. 9

C. 10

HF

s.e.e.

0.754

0.676

0.699

0.705

0.727

0.763

0.792

0.834

0.869

0.897

0.387

0.528

0.517

0.531

0.525

0.503

0.492

0.469

0.457

0.458

0.762

0.728

0.724

0.727

0.726

0.734

0.751

0.780

0.809

0.842

0.374

0.453

0.481

0.501

0.527

0.540

0.544

0.535

0.530

0.522

q
B3

2

s.e.e.
q

2

s.e.e. is standard error of estimates.

Table 4.10: QSAR Reports by Non-Crossvalidation Using SAMPLS by the Training
Set of 26 Molecules
Calculation
Level
HF/6-31G*
B3LYP/6-31G*

S.E.E.

R2

F Values

Steric.

Electro.

0.279
0.080

0.920
0.995

(n1 = 2, n2 = 23) 131.471
(n1 = 7, n2 = 18) 499.198

0.422
0.393

0.578
0.607

s.e.e. is standard error of estimates.

The application of the robust criteria as described in Section 2.2.3 is shown in Figures
4.26 and 4.27 for HF/6-31G* in the graphs of predicted pKi values vs experimental pKi
values. The training set and tests were subject to Equations 2.5 – 2.9; those equations
were used to calculate and confirm that the HF/6-31G* CoMFA model meets the robust
criteria as defined by Golbraikh and colleagues in Table 4.11 (2002, 2003).
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1.00

Test set:

Training set:
y = 1x - 2E-05
R² = 0.9196

0.50

y = 0.679x - 0.3876
R² = 0.9086

0.00

Predicted pki

-0.50

y = 0.8628x
R0² = 0.7856
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-1.50
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-2.00
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-3.00
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-0.5

0.5
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Figure 4.26 Graph of Predicted pKi vs Experimental pKi by the CoMFA model at HF/631G*.

1.75

Experimental pki

0.75

y = 1.0862x
R0'² = 0.863

-0.25
Test
-1.25

Linear (Test)

-2.25

-3.25
-3.25

-1.25

0.75

Predicted pki

Figure 4.27 Graph of Experimental pKi vs Predicted pKi for Test Set by the CoMFA
model at HF/6-31G*.
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Table 4.11:
(Sigma 2)

Equations (2.5 – 2.9)

Value

q2 > 0.5

q2 = 0.528

R2 > 0.6

R2 = 0.91

(R2 −R′2
0 )
R2

Results for QSAR Robust Criteria Equations 2.5 – 2.9 for HF/6-31G*

(R2 −R′2
0 )

< 0.1 and 0.85 ≤ k ≤ 1.15

R2

= 0.05 and 𝑘 = 1.09

|R20 − R′2
0 | = 0.08

|R20 − R′2
0 | < 0.3

The application of the robust criteria as described in Section 2.2.3 is shown in Figures
4.28 and 4.29 for B3LYP/6-31G* in the graphs of predicted pKi values vs experimental
pKi values. The training set and tests were subject to Equations 2.5 – 2.9; those equations
were used to calculate and confirm that the B3LYP/6-31G* CoMFA model meets the
robust criteria as defined by Golbraikh and colleagues in Table 4.12 (2002, 2003).
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1.00

Test set:

Training set:
y = 1x - 4E-06
R² = 0.9949

0.50

y = 0.6199x - 0.4606
R² = 0.8589
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Predicted pKi
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Figure 4.28 Graph of Predicted pKi vs Experimental pKi by the CoMFA model at
B3LYP/6-31G*.
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Figure 4.29 Graph of Experimental pKi vs Predicted pKi for Test Set by the CoMFA
model at B3LYP/6-31G*.
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Table 4.12:
(Sigma 2)

(R2 −R20 )
R2

Results for QSAR Robust Criteria Equations 2.5 – 2.9 for B3LYP/6-31G*

Equations (2.5 – 2.9)

Value

q2 > 0.5

q2 = 0.544

R2 > 0.6

R2 = 0.995
(R2 −R20 )

< 0.1 and 0.85 ≤ k ≤ 1.15

R2

= 0.06 and 𝑘 = 1.09

|R20 − R′2
0 | = 0.14

|R20 − R′2
0 | < 0.3

In summary, the bioactivity prediction for both models at HF/6-31G* and B3LYP/631G* were considered robust via PLS and the criteria set by Golbraikh and colleagues
(2002, 2003). Therefore, the model can serve as a means to predict other compounds for
sigma 2 activity.

4.5.4 Contour Maps of CoMFA Models
Contour maps from the CoMFA models were explored with the objective to understand
the desired sterics and electrostatics that could enhance the activity of a molecule,
enabling the design of new ligands. In the maps, green represents steric bulk desirable
whereas yellow represents steric bulk undesirable. In terms of electrostatics, the maps
depict red for negative charge desirable whereas blue represents positive charge as
desirable. The differences observed in the CoMFA contour maps between HF/6-31G*
and B3LYP/6-31G* were also explored.
Figure 4.30 and Figure 4.31 show the contour maps for compound 5 (PB 28),
which served as the template for the CoMFA model as well as the reference compound
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for the DISCOtech pharmacophore generation for the representative sigma 2 model. The
right side of Figures 4.30 and 4.31 show that electronegativity is preferable above the
cyclohexyl as well as bulk surrounding that area; on the left side it shows bulk around the
rings as well as a mix of positive and negative charge desirable. The calculation levels for
the CoMFA contour maps appear to be in good agreement visually.

Figure 4.30 CoMFA contour map of compound 5 (PB28) at HF/6-31G*.

Figure 4.31 CoMFA contour map of compound 5 (PB28) at B3LYP/6-31G*.
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The CoMFA contour maps for compound 19 were observed, as this molecule, based on
its aforementioned extremely high selectivity for sigma 2, is an excellent candidate for
bioactivity improvement. Figures 4.32 and 4.33 demonstrate the possibilities to add
electronegativity on the right side as well as bulk, in addition to there being opportunities
on the left side around the rings, to add bulk and positivity. This was explained further in
Section 4.6.

Figure 4.32 CoMFA contour map of compound 19 at HF/6-31G*.

Figure 4.33 CoMFA contour map of compound 19 at B3LYP/6-31G*.
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4.6 Design of New Sigma 2 Ligands

Utilizing the analysis conducted in Section 4.5.4, the design of new ligands was
conducted on compound 19, with various combinations to increase electronegativity or
positivity as well as bulk in various locations. There were four main locations
considered based on the CoMFA contour maps as shown in Table 4.13, with improved
bioactivity values noted in bold. Note that the literature pKi for compound 19 is
-0.9138.

Table 4.13: Compound 19-based New Ligands

Comp.

R1

R2

R3

R4

HF/6-31G*

B3LYP/
6-31G*

Predicted pKi
19

H

CH3

H

H

-0.7067

-0.9242

53

Cl

CH3

H

H

-0.2655

-0.4803

54

Cl

tbutyl

H

H

-0.1777

-0.3961

55

COOH

CH2-NH2

NH2

H

-0.3564

-0.4336

56

COOH

CH3

H

H

-0.3028

-0.6155

57

H

tbutyl

H

H

-0.5156

-0.833

58

F

CH3

H

H

59

H

CH3

NH2

H

-0.2448
-0.7367

-0.6145
-0.6311
-0.4811
-1.1311
-0.8609

60

H

CH2-NH2

H

H

-0.4522

61

Cl

C(CH3)(CH2NH2)(CH2NH2)

H

H

62

H

CH3

H

tbutyl

-0.6485
-0.7117
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The best R-group combinations, yielding highest activity improvements, were selected
for discussion. In the case of adding bulk (tbutyl) at the R2 location and Cl at the R1
location, the predicted pKi improved from -0.7067 to -0.1777 for HF/6-31G* and from 0.9242 to -0.3961 for B3LYP/6-31G*. As explained in Chapter 3, higher pKi means
increased bioactivity. A pKi value could mean a Ki value of 1.5 nM which is an
improvement over the literature value of 8.2 nM for the molecule. The corresponding
contour maps are in Figures 4.34 and 4.35.

Figure 4.34 CoMFA contour map of compound 54 at HF/6-31G*.
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Figure 4.35 CoMFA contour map of compound 54 at B3LYP/6-31G*.

Another promising combination, yielding high activity improvement, was the case of
adding N atoms (increasing positivity) at R2 and R3. There was fairly good overlap of
these additions into the blue areas of the contour map. The predicted pKi improved from
-0.7067 to -0.3564 for HF/6-31G* and -0.9242 to -0.4336. The corresponding contour
maps are in Figures 4.36 and 4.37.

Figure 4.36 CoMFA contour map of compound 55 at HF/6-31G*.
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Figure 4.37 CoMFA contour map of compound 55 at B3LYP/6-31G*.

The case of increasing electronegativity on the right cyclohexyl ring with the addition of
a Cl atom helped increase bioactivity for compound 19 as well on both calculation levels
as demonstrated with compound 58. The predicted pKi value went from -0.7067 to
-0.2655 for HF/6-31G* and -.9242 and -0.4803 for B3LYP/6-31G*. The corresponding
countour maps are in Figures 4.38 and 4.39.

Figure 4.38 CoMFA contour map of compound 53 at HF/6-31G*.
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Figure 4.39 CoMFA contour map of compound 53 at B3LYP/6-31G*.

Certainly these are promising results, lending to the possibility that the newly
predicted highly active ligands could be synthesized and potentially used in the future as
drug candidates, particularly as potentially highly selective sigma 2 compounds since
these were designed from compound 19. Highly active, selective sigma 2 compounds are
rare as evidenced by the data set and by other researchers. In fact, even compound 5, PB
28, does not have a very high selectivity (σ1/ σ2): 40 vs 1573 for compound 19. Therefore,
we can see the value for improving activity for compound 19; initial results were
excellent with a possible high activity at 1.5 nM. Additional contour maps for newly
designed ligands are located in the APPENDIX.
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CHAPTER 5
COMPARISON OF SIGMA 1 AND SIGMA 2 RECEPTOR LIGANDS

5.1 Sigma 1 and Sigma 2 Receptor Ligand Differences
Part of the objective of this study was to determine what differentiates a ligand from
being bioactive for a sigma 1 receptor vs a sigma 2 receptor. As mentioned in Chapter 3
and 4, there were noted differences in the comprehensive pharmacophores. Figures 3.20
and 4.18 represent the two different comprehensive pharmacophores. As stated, these
pharmacophores drove the alignment techniques used for the corresponding CoMFA
models which were considered robust and highly predictive for bioactivity. Therefore,
one can presume that these pharmacophores generated by DISCOtech are viable models,
in addition to the consistent framework they had from previous work in the Gund group.
Particularly for sigma 2, the current model postulated resolves the previous models into a
hybrid model and again shows strong representation for different classes of compounds,
with a highly active reference.
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Figure 3.20 (repeat) Comprehensive DISCOtech pharmacophore derivation for Sigma 1.
Purple sphere = acceptor site, red sphere = positive nitrogen and green sphere =
aromatic/hydrophobic center.

Figure 4.18 (repeat) Comprehensive DISCOtech pharmacophore derivation for Sigma 2.
Purple sphere = acceptor site, red sphere = positive nitrogen and blue-green spheres =
hydrophobic centers.

The following Figures 5.1 - 5.4, demonstrate the test compound, Haloperidol, in the
HF/6-31G* and B3LYP/6-31G* CoMFA contour maps. Interestingly, Haloperidol in
sigma 1 maps appears to have slightly more distribution of bulk on both ends of the
molecule and somewhat around the molecule. Haloperidol in sigma 2 maps, however,
appears to have more distinct bulk forms, one on each side of the molecule and not
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necessarily around the whole molecule. Further, sigma 2 appears to favor more positivity
as evidenced by the color blue in the map.

Figure 5.1 Haloperidol at HF/6-31G* sigma 1 CoMFA contour map.

Figure 5.2 Haloperidol at HF/6-31G* in sigma 2 CoMFA contour map.
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Figure 5.3 Haloperidol at B3LYP/6-31G* in sigma 1 CoMFA contour map.

Figure 5.4 Haloperidol at B3LYP/6-31G* in sigma 2 CoMFA contour map.
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CHAPTER 6
SUGGESTIONS FOR FURTHER WORK

Following the completion of the analysis around the sigma 1 and sigma 2 ligands studied
in this work, the researcher concludes that the objectives of the study were met – from
deriving pharmacophores for both receptor ligand subtypes, to designing comprehensive
pharmacophores, to applying the designed comprehensive pharmacophores to the
CoMFA alignments and models, to yielding robust CoMFA models and consequently
useful contour maps which led to the understanding of the differences of sigma 1 and
sigma 2 receptor ligands in addition to enabling the design of several new, highly
bioactive ligands. Additionally, some comparison to previous work in the Gund group as
well as other researchers’ models globally was conducted.
Future work should encompass delving further into the analysis around sigma 1 vs
sigma 2. Now that these CoMFA models have been confirmed as highly robust and
predictive, they could be used for additional screening work for design of new ligands or
prediction of bioactivity for various molecules. For instance, perhaps molecules could be
designed to shift to either sigma 1 or sigma 2 activity depending on the need. If that
design process could yield successful results, then it would be clear that there is indeed
understanding of the differences between sigma 1 and sigma 2. Further, the models could
be used to test other compounds for sigma 1 or sigma 2 prior to being synthesized in the
lab.
Many researchers appear to modify the design of a ligand by varying ring size or
shifting a substituent. Another approach could be to test those ideas in the CoMFA
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models or more importantly, consider the bulk and electrostatics according to the models
for the design initially.
Further work should be done to understand if flexible alignment is truly
appropriate or sound. Many researchers claim this to be the case and in general the
software programs expect that one will be mostly conducting flexible alignment. Perhaps
some studies to conduct flexible alignment while measuring the energy differences and
simultaneously comparing the results to the data generated here may be a first step in that
process.
Finally, pharmacophore and CoMFA models can be expanded to include
additional classes as new data is published.
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APPENDIX A
ADDITIONAL CONTOUR MAPS FOR SIGMA 1 LIGANDS

The figures in APPENDIX A represent additional contour maps of the lead compounds
for each sigma 1 class as well as the entire training set.

Figure A.1 Contour map of sigma 1 compound 1 at HF/6-31G*.

Figure A.2 Contour map of sigma 1 compund1 at B3LYP/6-31G*.

Figure A.3 Contour map of sigma 1 compound 9 at HF/6-31G*.
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Figure A.4 Contour map of sigma 1 compound 9 at B3LYP/6-31G*.

Figure A.5 Contour map of sigma 1 compound 22 at HF/6-31G*.

Figure A.6 Contour map of c sigma 1 compound 22 at B3LYP/6-31G*.
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Figure A.7 Contour map of sigma 1 training set at HF/6-31G*.

Figure A.8 Contour map of sigma 1 training set at B3LYP/6-31G*.
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APPENDIX B
ADDITIONAL CONTOUR MAPS FOR SIGMA 2 LIGANDS

The figures in APPENDIX B represent additional contour maps of the lead compounds
for each sigma 2 class as well as the contour maps of the entire training set.

Figure B.1 Contour map of sigma 2 compound 37 at HF/6-31G*.

Figure B.2 Contour map of sigma 2 compound 37 at B3LYP/6-31G*.

Figure B.3 Contour map of sigma 2 compound 43 at HF/6-31G*.
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Figure B.4 Contour map of sigma 2 compound 43at B3LYP/6-31G*.

Figure B.5 Contour map of sigma 2 compound 52 at HF/6-31G*.

Figure B.6 Contour map of sigma 2 compound 52at B3LYP/6-31G*.

Figure B.7 Contour map of sigma 2 training set at HF/6-31G*.
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Figure B.8 Contour map of sigma 2 training set B3LYP/6-31G*.
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APPENDIX C
ADDITIONAL CONTOUR MAPS FOR NEWLY DESIGNED SIGMA 2
LIGANDS

The figures in APPENDIX C represent additional contour maps of the newly designed
sigma 2 ligands.

Figure C.1 Contour map of sigma 2 compound 56 at HF/6-31G*.

Figure C.2 Contour map of c sigma 2 compound 56 at B3LYP/6-31G*.

Figure C.3 Contour map of sigma 2 compound 57 at HF/6-31G*.

150

Figure C.4 Contour map of sigma 2 compound 57at B3LYP/6-31G*.

Figure C.5 Contour map of sigma 2 compound 58 at HF/6-31G*.

Figure C.6 Contour map of sigma 2 compound 58 at B3LYP/6-31G*.
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Figure C.7 Contour map of sigma 2 compound 59 at HF/6-31G*.

Figure C.8 Contour map of sigma 2 compound 59 at B3LYP/6-31G*.

Figure C.9 Contour map of sigma 2 compound 60 at HF/6-31G*.

Figure C.10 Contour map of sigma 2 compound 60at B3LYP/6-31G*.
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Figure C.11 Contour map of sigma 2 compound 61 at HF/6-31G*.

Figure C.12 Contour map of sigma 2 compound 61at B3LYP/6-31G*.

Figure C.13 Contour map of sigma 2 compound 62 at HF/6-31G*.

Figure C.14 Contour map of sigma 2 compound 62at B3LYP/6-31G*.
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